<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Biochem Pharmacol</span><span class="iso-abbrev" title="iso-abbrev">Biochem Pharmacol</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Biochemical Pharmacology</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">0006-2952</span><span class="issn-epub" tagx="issn" title="issn-epub">1873-2968</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Published by Elsevier Inc.</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7392210">7392210</a></span><span class="pii" title="pii">S0006-2952(20)30420-2</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1016/j.bcp.2020.114184">10.1016/j.bcp.2020.114184</a></span><span class="publisher-id" title="publisher-id">114184</span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Unsolicited Perspective</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chakraborty</span><span class="given-names" tagx="given-names" title="given-names">Rohan</span></span></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parvez</span><span class="given-names" tagx="given-names" title="given-names">Suhel</span></span><a href="#cor1">â�Ž</a></span><span class="citation_author_institution" id="af005">[], </span></div> <div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">â�Ž</span>Corresponding author at: Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.</div> </div><span class="pub-date-pmc-release" title="pub-date-pmc-release">pmc-release: <span>2020-7-7</span></span><span class="pub-date-ppub" title="pub-date-ppub">ppub: <span>2020-10</span></span><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-7-7</span></span><span class="volume" tagx="volume" title="volume">180</span><span class="fpage" tagx="fpage" title="fpage">114184</span><span class="lpage" tagx="lpage" title="lpage">114184</span><span class="history" title="history"><span class="received" title="received">received: 2020-6-24</span><span class="rev-recd" title="rev-recd">rev-recd: 2020-7-24</span><span class="accepted" title="accepted">accepted: 2020-7-27</span></span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder" />, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</span></span></div> <div class="abstract" title="abstract"> <div class="title" tagx="title" title="title">
Graphical abstract</div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/" /></div>  </div> </div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <p>COVID-19, the greatest public health emergency of the 21st century, has affected 215 countries and territories around the world resulting in 15,151,738 confirmed cases and 621,121 deaths. The outbreak has continued at breakneck pace despite stringent public health measures, ravaging the global economy and causing profound human casualties. Vaccination is currently the best bet for the prevention of COVID-19. Still, in its absence, there has been considerable interest in repurposing existing therapeutic agents to reduce the severity of the illness and ease the burden on the already strained healthcare systems. This review outlines the current evidence regarding proposed treatments- experimental or repurposed, for COVID-19, and gives an insight into the clinical trial landscape for drugs as well as vaccines.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
COVID-19</div> <div class="kwd" title="kwd">
SARS-CoV-2</div> <div class="kwd" title="kwd">
Coronavirus</div> <div class="kwd" title="kwd">
Drugs</div> <div class="kwd" title="kwd">
Vaccines</div> <div class="kwd" title="kwd">
Clinical trials</div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Abbreviations</div> <div class="kwd" title="kwd">
COVID-19, Coronavirus Disease 2019</div> <div class="kwd" title="kwd">
SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2</div> <div class="kwd" title="kwd">
WHO, World Health Organization</div> <div class="kwd" title="kwd">
ICTV, International Committee on Taxonomy of Viruses</div> <div class="kwd" title="kwd">
ARDS, acute respiratory distress syndrome</div> <div class="kwd" title="kwd">
SARS, Severe Acute Respiratory Syndrome</div> <div class="kwd" title="kwd">
MERS, Middle East Respiratory Syndrome</div> <div class="kwd" title="kwd">
R<sub>0</sub>, reproductive ratio</div> <div class="kwd" title="kwd">
SI, Serial Interval</div> <div class="kwd" title="kwd">
PPE, Personal Protective Equipment</div> <div class="kwd" title="kwd">
ACE2, angiotensin I converting enzyme 2</div> <div class="kwd" title="kwd">
RAS, Renin-Angiotensin System</div> <div class="kwd" title="kwd">
ATII, alveolar Type II cells</div> <div class="kwd" title="kwd">
RdRp, RNA-dependent RNA polymerase</div> <div class="kwd" title="kwd">
TMPRSS2, type-2 transmembrane serine protease</div> <div class="kwd" title="kwd">
IL-6, interleukin 6</div> <div class="kwd" title="kwd">
TNFÎ±, tumor necrosis factor Î±</div> <div class="kwd" title="kwd">
MCP-1, monocyte chemoattractant protein-1</div> <div class="kwd" title="kwd">
NK, natural killer cells</div> <div class="kwd" title="kwd">
S protein, viral spike protein</div> <div class="kwd" title="kwd">
aAPC, artificial antigen-presenting cells</div> <div class="kwd" title="kwd">
CP, Convalescent Plasma therapy</div> <div class="kwd" title="kwd">
CRS, Cytokine-release syndromes</div> <div class="kwd" title="kwd">
ADR, Adverse Drug Reactions</div> </div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1</span><div class="title" tagx="title" title="title">
Introduction</div> <p id="p0005">In late 2019, there was a sudden surge in the number of individuals being admitted to local hospitals of Wuhan, in the Hubei Province of China, with a pneumonia-like illness of unknown etiology <a href="#b0005">[1]</a>. Although results from preliminary epidemiological investigations pointed towards a zoonotic origin from a local seafood market in Huanan, the exponential increase in the number of cases suggested the possibility of human-to-human transmission <a href="#b0010">[2]</a>, <a href="#b0015">[3]</a>. The World Health Organization (WHO) was notified of the outbreak by the Chinese authorities on December 31, 2019. By January 7, 2020, scientists had isolated a novel coronavirus from the lower respiratory tract samples of patients who were admitted to a hospital in Wuhan <a href="#b0020">[4]</a>. This pathogen was later termed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV) <a href="#b0025">[5]</a>. The WHO declared this novel viral disease a Public Health Emergency of International Concern on 30 January 2020, and subsequently termed it as COVID-19 (Coronavirus Disease 2019) <a href="#b0030">[6]</a> on February 11, 2020. The first fatality was reported on Jan 11, 2020. The mass migration of people during the Chinese New Year fuelled the rapid spread of the disease to all parts of the globe, which led to the official declaration of COVID-19 as a pandemic <a href="#b0035">[7]</a> by the WHO on March 11, 2020. COVID-19 has wreaked havoc worldwide, resulting in 15,151,738 confirmed cases and 621,121 deaths across 215 countries and territories <a href="#b0040">[8]</a> as of July 22, 2020. Despite stringent public health measures, the outbreak has continued at a breakneck pace and has laid bare the glaring inadequacies of the present healthcare systems around the world.</p> </div> <div class="virology" title="sec"><span class="label" tagx="label" title="label">2</span><div class="title" tagx="title" title="title">
Virology</div> <p id="p0010">Coronaviruses (derived from the Latin word corona, meaning crown) are positive sense, single-stranded enveloped RNA viruses with a diameter of 60Â nm to 140Â nm, and are widely dispersed in nature <a href="#b0020">[4]</a>. Four (hCoV-229E, OC43, NL63 and HKU1) out of the seven species of beta-coronaviruses found in humans cause mild illnesses of the upper respiratory tract such as common cold (also caused by rhinoviruses). Two other kinds, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), are considerably more dangerous (mortality rates of 9.6% and 35% respectively <a href="#b0045">[9]</a>, <a href="#b0050">[10]</a>). SARS-CoV first emerged in late 2002 in China and spread rapidly to other parts of the world from Hong Kong via air travel. The virus was believed to have originated from a bat (primary host) from where it mutated to infect the intermediate host- Civet cats (a nocturnal mammal sold for meat in China) and subsequently infected humans <a href="#b0055">[11]</a>. It turned into an epidemic with over 8000 cases and 744 deaths <a href="#b0060">[12]</a>. Almost a decade later, MERS emerged in the Middle East with Dromedary Camel as the intermediate host from which it mutated enough to affect humans, resulting in 2494 cases and 858 deaths <a href="#b0065">[13]</a>. SARS-CoV-2, the pathogenic factor for COVID-19, is a novel zoonotic RNA betacoronavirus. Several studies have conducted phylogenetic analyses of SARS-CoV-2 to determine its sequence homology with other viruses of the family <i>Coronaviridae</i><a href="#b0020">[4]</a>, <a href="#b0070">[14]</a>, <a href="#b0075">[15]</a>, <a href="#b0080">[16]</a>, <a href="#b0085">[17]</a>, <a href="#b0090">[18]</a>. It has been reported that SARS-CoV-2 shares a 79.6% sequence homology with SARS-CoV, and 96.2% resemblance with bat coronavirus (HKU4) <a href="#b0070">[14]</a>. <a href="#f0005">Fig. 1</a> depicts the structure of SARS-CoV-2. While the exact source of the virus remains a mystery, it is widely reported to have originated from a bat <a href="#b0020">[4]</a>, <a href="#b0070">[14]</a> and made its way to humans via an intermediate animal host, the pangolin <a href="#b0055">[11]</a>, <a href="#b0075">[15]</a>, a nocturnal mammal that is highly trafficked around the world for the medicinal properties of its scales and its meat. The ecological origin and subsequent transmission of the three aforementioned Coronavirus species are illustrated in <a href="#f0010">Fig. 2</a> . </p><div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Fig. 1</span></a></div>   <p>Diagrammatic representation of the structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The figure represents the viral structure of SARS-CoV-2. The spike glycoprotein (S protein) confers a crown like appearance to the virus, hence the name â€˜Coronavirusâ€™. The S protein mediates the binding of the virus to cellular receptors. The role of hemagglutinin-esterase (HE) in Coronaviruses is poorly understood but it is reported to influence virion attachment in other viruses.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Fig. 2</span></a></div>   <p>Ecological origin and transmission of different species of Coronaviruses. This schematic representation illustrates the ecological origin, different animal hosts, and the subsequent transmission of SARS-CoV, MERS-CoV, and SARS-CoV-2 to the human population, eventually resulting in the three major epidemics/pandemic of the 21st century.</p>   </div> <p /> </div> <div class="clinicalfeaturesandsusceptibility" title="sec"><span class="label" tagx="label" title="label">3</span><div class="title" tagx="title" title="title">
Clinical features and susceptibility</div> <p id="p0015">People of all age groups are susceptible to COVID-19. The symptoms, which have been found to resemble those of the seasonal flu (Influenza), include fever, cough, sore throat, headache, fatigue, myalgia, loss of smell and taste, and dyspnea. Up to 80% of cases are asymptomatic or have mild disease <a href="#b0095">[19]</a>. In some patients, underlying co-morbidities can further exacerbate the diseased condition, leading to pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ dysfunction by the end of the first week, eventually proving fatal.</p> </div> <div class="transmission" title="sec"><span class="label" tagx="label" title="label">4</span><div class="title" tagx="title" title="title">
Transmission</div> <p id="p0020">Inhalation of respiratory droplets generated by symptomatic patientsâ€™ cough and sneeze is the main mode of transmission of COVID-19. Infected droplets can spread to distances of up to 2Â m and deposit on surfaces, which can act as potential fomites for transmission of the virus to seemingly healthy individuals who touch their mucosa (mouth, nose) and conjunctiva (eyes) without proper sanitization. Asymptomatic or pre-symptomatic people can also spread the infection. The virus is also believed to be present in the stool, and transmission via the feco-oral route cannot be ruled out <a href="#b0100">[20]</a>. There is currently no evidence of transmission of the virus from a pregnant mother to her fetus via transplacental route.</p> </div> <div class="physicochemicalproperties" title="sec"><span class="label" tagx="label" title="label">5</span><div class="title" tagx="title" title="title">
Physicochemical properties</div> <p id="p0025">SARS-CoV-2 can remain viable on surfaces like plastic and stainless steel for up to 72Â h in favourable atmospheric conditions <a href="#b0105">[21]</a> but is susceptible to common disinfectants like sodium hypochlorite, hydrogen peroxide, diethyl ether, 75% ethanol, chloroform etc <a href="#b0110">[22]</a>. Soap is found to be equally effective since it readily dissolves the lipid bilayer of the virus. SARS-CoV-2 can also be inactivated by UV or when heated at 60Â Â°C for 30Â min <a href="#b0115">[23]</a>, <a href="#b0120">[24]</a>.</p> </div> <div class="epidemiology" title="sec"><span class="label" tagx="label" title="label">6</span><div class="title" tagx="title" title="title">
Epidemiology</div> <p id="p0030">Despite being relatively more benign than its two ancestors, SARS-CoV-2 has crossed the 15 million cases mark worldwide, aided in part by inadequate risk assessment regarding the urgency of the situation. However, the overriding reasons for its exponential growth are the high reproductive ratio (R<sub>0</sub>) â€" ranging from 2 to 6.47 <a href="#b0125">[25]</a>, the long incubation period of 2 to 14Â days (median 5Â days) and a Serial Interval (SI) of 5â€"7.5Â days <a href="#b0130">[26]</a>, which are indicative of an infectious disease that has the potential of rapidly turning into a pandemic. Sanche et al. recently suggested that the disease had a median R<sub>0</sub> of 5.7 (95% CI of 3.8â€"8.9) and SI of 6â€"9Â days in China during the initial period of the outbreak <a href="#b0135">[27]</a>. In comparison, the R<sub>0</sub> of SARS was 2 and 1.3 for the 2009 H1N1 Influenza <a href="#b0130">[26]</a>.The mortality rate for COVID-19 ranges between 2 and 5%, with ARDS being the leading cause of death <a href="#b0020">[4]</a>.</p> </div> <div class="currentmanagement" title="sec"><span class="label" tagx="label" title="label">7</span><div class="title" tagx="title" title="title">
Current management</div> <p id="p0035">In the absence of any established pharmacological agents, supportive care remains the cornerstone of clinical management for COVID-19. Prevention involves isolation of suspected cases, home quarantine for the healthy, and the use of effective Personal Protective Equipment (PPE) to reduce the risk of interpersonal transmission. The conspicuous absence of any proven interventions for COVID-19 <a href="#b0140">[28]</a>, coupled with the alarmingly high infectivity of SARS-CoV-2 has rendered this pandemic an unmitigated disaster. Swiftly expanding knowledge of the virology of SARS-CoV-2 has laid the groundwork for the identification of effective therapeutic agents for the prevention and treatment of the disease by providing potential drug targets. This review outlines the measures currently in place to curb its spread and gives a glimpse into the roadmap for the development of a vaccine.</p> </div> <div class="methodology" title="sec"><span class="label" tagx="label" title="label">8</span><div class="title" tagx="title" title="title">
Methodology</div> <p id="p0040">A literature search was conducted using PubMed to identify relevant English-language articles published through July 21, 2020. Search terms included Coronavirus, SARS-CoV-2 and COVID-19. Active clinical trials were identified using the search terms COVID-19 and SARS-CoV-2 on ClinicalTrials.gov till July 21, 2020. The search yielded 2713 trials, with 1393 actively recruiting trials specific to COVID-19. Of these, 1174 were observational trials while 1515 were intervention trials for the treatment of COVID-19. Among these, 75 were Phase 4, 350 were Phase 3, 598 were Phase 2, 171 were Phase 1, and 26 were Early Phase 1 trials. 493 trials were not categorized by any particular phase or were not applicable. Further, 228 studies had been listed completed at the time of writing. Results are still awaited for all completed studies.</p> </div> <div class="pathophysiology" title="sec"><span class="label" tagx="label" title="label">9</span><div class="title" tagx="title" title="title">
Pathophysiology</div> <p id="p0045">SARS-CoV-2 enters human cells through its Spike (S) protein- a type I surface glycoprotein, and binds to the angiotensin I converting enzyme 2 (ACE2) receptor <a href="#b0145">[29]</a>. ACE2 is a type 1 transmembrane aminopeptidase expressed in the heart and lungs. It negatively regulates the Renin-Angiotensin System (RAS) and plays a significant role in neurohumoral regulation of the cardiovascular system. When SARS-CoV-2 binds to ACE2, it alters the ACE2 signaling pathways, potentially causing acute myocardial and lung injury <a href="#b0150">[30]</a>, <a href="#b0155">[31]</a>. ACE2 receptors are abundantly distributed in the epithelia of the lung- especially the alveolar Type II (ATII) cells. Once the virus binds to the receptor, it spreads widely on entering the blood circulation. <a href="#f0015">Fig. 3</a> shows a schematic representation of the viral replication of SARS-CoV-2 inside a host ATII cell. ACE2 receptors are also said to be present in the liver, digestive organs and kidneys. These tissues and organs could thus be potential targets for SARS-CoV-2 invasion <a href="#b0160">[32]</a>. This explains why many patients with COVID-19 present with extra-pulmonary symptoms <a href="#b0010">[2]</a>. When the over activated immune system is engaged in killing the virus, there is a sharp spike in the production of inflammatory factors, such as IL-2, IL-6, GCSF, MCP-1, TNFÎ±, etc. This, in turn, may pave the way for a cytokine storm <a href="#b0010">[2]</a> and eventually lead to ARDS, secondary infections and multi-organ damage, resulting in death. </p><div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Fig. 3</span></a></div>   <p>Schematic representation of the entry of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) into host cell, its viral lifecycle and potential drug targets. The above-mentioned figure depicts the viral processing of SARS-CoV-2 within host cells. S protein has a major role in binding of the virus to the host receptor cells. It attaches itself to the ACE2 receptor of the human host cell, leading to the release of the viral RNA into the host cell which triggers a cascade that ultimately results in respiratory infection. Select repurposed drugs and their target sites of action are also represented in this schematic. ACE2: angiotensin-converting enzyme 2; S protein: spike protein; TMPRSS2: type 2 <i>trans</i>-membrane serine protease and IL-6: interleukin 6.</p>   </div> <p /> </div> <div class="pharmacologicaltreatmentswithpotentialclinicalbenefits" title="sec"><span class="label" tagx="label" title="label">10</span><div class="title" tagx="title" title="title">
Pharmacological treatments with potential clinical benefits</div> <p id="p0050">In the months since the novel coronavirus burst onto the scene, drug makers small and large have scrambled to put their best foot forward in an attempt to thwart the pandemic. Some are taking cues from older antivirals, while others are aiming to develop novel therapeutic agents to treat COVID-19. Vaccine development, convalescent plasma therapy, cell-based therapies and monoclonal antibodies are some of the potential approaches being targeted by researchers worldwide. However, drug development is an expensive and time-consuming endeavor with a high attrition rate <a href="#b0165">[33]</a>. The enormity of the current global health emergency means that time is of the essence. Thus, there has been considerable interest in repurposing existing drugs and expediting the development of vaccines, to allow rapid identification of suitable drug candidates. The dearth of proven clinical data on therapeutic agents for COVID-19 has led to a reliance on existing therapies for other viruses such as SARS-CoV-1, MERS-CoV, and HIV etc. It is unclear whether the data from repurposed antiviral drugs can be extrapolated to SARS-CoV-2, as unlike antibiotics, antivirals are specific for a particular virus in most cases. <a href="#t0005">Table 1</a> lists some of the potential therapeutic agents that have been used as repurposed drugs for COVID-19 treatment. Their sites and mechanisms of action against SARS-CoV-2 are illustrated in <a href="#f0015">Fig. 3</a>. <div class="table-wrap_UNKNOWN" position="float" id="t0005"><span class="label" tagx="label" title="label">Table 1</span> </div></p><p>Potential therapeutic agents as repurposed drugs for the treatment of COVID-19.</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Drug (Year of first usage)</th> <th>Class &amp;amp; Type</th> <th>Rationale for Use</th> <th>Target Disease</th> <th>Dosage in Current Trials</th> <th>Supportive Evidence</th> <th>Caveats</th> <th>References</th> </tr> </thead> <tbody> <tr> <td><b>Remdesivir</b>(2014)</td> <td>Antiviral; Adenosine nucleotide analogue</td> <td>Acts as an RNA-chain terminator by binding to RNA dependent RNA polymerase (RdRP).</td> <td>Ebola</td> <td>200Â mg intravenously (IV) on day 1 followed by 100Â mg IV daily for up to 10Â days (NCT04292899)</td> <td>Effective against SARS and MERS in-vitro</td> <td>Not currently FDA-approved. Can only be obtained via compassionate use.</td> <td><a href="#b0170">[34]</a>, <a href="#b0175">[35]</a>, <a href="#b0180">[36]</a>, <a href="#b0185">[37]</a></td> </tr> <tr> <td><b>Lopinavir/Ritonavir (LPV/r)</b>(2000)</td> <td>Antiviral; Protease inhibitors</td> <td>HIV type 1 aspartate protease inhibitor with inhibitory activity against SARS-CoV in-vitro.</td> <td>HIV</td> <td>400/100Â mg twice daily for 14Â days. (NCT04321174)</td> <td>Effective against SARS-CoV-1 both in vitro and human studies</td> <td>Current data suggest a limited role in treatment of COVID-19.</td> <td><a href="#b0225">[45]</a>, <a href="#b0230">[46]</a>, <a href="#b0235">[47]</a></td> </tr> <tr> <td><b>Oseltamivir</b>(1999)</td> <td>Antiviral; Neuraminidase inhibitor</td> <td>Inhibits viral replication.</td> <td>Influenza</td> <td>75Â mg orally twice a day for 5Â days (NCT04338698)</td> <td>No in-vitro activity against SARS-CoV</td> <td>Has no role in the management of COVID-19 once influenza has been ruled out. No data against SARS.</td> <td><a href="#b0250">[50]</a></td> </tr> <tr> <td><b>Favipiravir</b>(2014)</td> <td>Antiviral; RNA polymerase inhibitor</td> <td>RNA-dependent RNA polymerase inhibitor. Also involved in blocking viral replication.</td> <td>Influenza, arenavirus, filovirus</td> <td>1600Â mg twice daily on day 1, then 600Â mg twice daily thereafter for 7Â days (NCT04310228)</td> <td>In vitro activity seen against SARS-CoV-2</td> <td>No available data on its efficacy and safety for the treatment of COVID-19</td> <td><a href="#b0170">[34]</a>, <a href="#b0260">[52]</a>, <a href="#b0265">[53]</a></td> </tr> <tr> <td><b>Ribavirin</b> (1986)</td> <td>Antiviral; Nucleoside analogue</td> <td>Inhibits viral RNA synthesis and mRNA capping.</td> <td>Syncytial virus, viral hemorrhagic fever,</td> <td>400Â mg twice daily for 14Â days (NCT04276688)</td> <td>No evidence in SARS and MERS</td> <td>Risks of ADR (hematologic toxicity, teratogenicity &amp;amp; contraindications in pregnancy) outweigh potential clinical benefit.</td> <td><a href="#b0170">[34]</a>, <a href="#b0250">[50]</a></td> </tr> <tr> <td><b>Camostatmesylate</b> (2006)</td> <td>Protease inhibitors</td> <td>Blocks viral maturation and entry to cells. Inhibits TMPRSS2.</td> <td>Pancreatitis</td> <td>2 Ã— 100 mg pills 3 times daily for 5Â days (NCT04321096)</td> <td>Effectively blocked SARS-CoV-2 in lung cells in vitro. Also showed antiviral activity in an animal model for SARS-CoV infection</td> <td>Limited data available.</td> <td><a href="#b0285">[57]</a>, <a href="#b0290">[58]</a></td> </tr> <tr> <td><b>Hydroxychloroquine / chloroquine</b> (HCQ/CQ) (1955/1934)</td> <td>Antimalarial</td> <td>Block viral entry into cells by inhibiting glycosylation of host receptors, proteolytic processing, and endosomal acidification.</td> <td>Malaria</td> <td>Chloroquine: 500Â mg twice daily for 10Â days<br /><br />Hydroxychloroquine: 400Â mg twice dailyÂ Ã—Â 1Â day then 200Â mg twice dailyÂ Ã—Â 5Â days (NCT04345692)</td> <td>In vitro activity against SARS-CoV-2</td> <td>Paucity of adequate data to validate their use in COVID-19.Concerns of cardiac arrhythmias</td> <td><a href="#b0260">[52]</a>, <a href="#b0295">[59]</a>, <a href="#b0305">[61]</a></td> </tr> <tr> <td><b>Tocilizumab</b> (2005)</td> <td>Monoclonal Antibody</td> <td>IL-6 inhibitor. May block cytokine storm in COVID-19 patients.</td> <td>Rheumatoid arthritis</td> <td>8Â mg/kg IV (up to a maximum of 800Â mg per dose), with an interval of 12Â h(NCT04317092)</td> <td>No data on SARS or MERS.</td> <td>Limited data to support current use.</td> <td><a href="#b0335">[67]</a></td> </tr> <tr> <td><b>Methylpred-nisolone</b> (1957)</td> <td>Corticosteroids</td> <td>Potent anti-inflammatory and antifibrotic properties; May prevent â€œcytokine stormâ€�; reduce pulmonary and systemic inflammation in pneumonia.</td> <td>Arthritis, psoriasis, etc.</td> <td>120Â mg/day IV infusion for 3Â days (NCT04345445)</td> <td>No impact on clinical outcomes in SARS</td> <td>No proven benefit for their use in COVID-19. Risks of ADRs outweigh the benefits</td> <td><a href="#b0365">[73]</a>, <a href="#b0370">[74]</a></td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>This table represents a list of repurposed therapeutic agents that are being used for the treatment of COVID-19, their class, mechanism of action, dosage, original target disease, and evidence supporting their use in COVID-19 patients.</p> </div> </div>  <p /> <div class="reviewofselectedrepurposeddrugs" title="sec"><span class="label" tagx="label" title="label">10.1</span><div class="title" tagx="title" title="title">
Review of selected repurposed drugs</div> <div class="antivirals" title="sec"><span class="label" tagx="label" title="label">10.1.1</span><div class="title" tagx="title" title="title">
Antivirals</div> <div class="remdesivir" title="sec"><span class="label" tagx="label" title="label">10.1.1.1</span><div class="title" tagx="title" title="title">
Remdesivir</div> <p id="p0055">Remdesivir, a monophosphate prodrug of an adenosine analog, was originally developed to combat the Ebola outbreak in 2014. It has been highly touted as a potential antiviral drug for COVID-19. It has been shown to have potent in-vitro activity against SARS-CoV-2 (EC<sub>50</sub> of 0.77Â Î¼M <a href="#b0170">[34]</a>), SARS-CoV-1 and MERS-CoV <a href="#b0175">[35]</a>. Because of its high selectivity for viral polymerases, Remdesivir is less likely to cause toxicity in humans. The drug also exhibits a high genetic barrier to resistance in coronaviruses and its long intracellular half-life is conducive for once-a-day dosing <a href="#b0180">[36]</a>. There are currently 38 registered trials listed on ClinicalTrials.gov for investigating the efficacy of this drug. Preliminary results from a small cohort show clinical improvement in 68% of hospitalized patients <a href="#b0185">[37]</a> on administration of Remdesivir. However, the small sample size and the lack of a control group limit its significance. Wang et al. reported that in a randomized, double-blind, placebo-controlled, multicentre trial of 237 participants (NCT04257656), Remdesivir did not exhibit significant clinical benefits <a href="#b0190">[38]</a>. On April 29, the US NIH reported that in a high powered RCT of 1063 participants, patients in the Remdesivir group had shown a 31% faster time to recovery (median 11Â days) <a href="#b0195">[39]</a> than those in the placebo group (15Â days) (pÂ <div class="â_UNKNOWN" href="#b0200">
[40] for COVID-19 patients in the United States. It has also been approved for therapeutic use in COVID-19 patients by the regulatory bodies of Japan, Australia, Singapore, and Europe <a href="#b0205">[41]</a>. The use of Remdesivir might prove to have a measurable impact on healthcare capacity by minimizing the length of hospital stay and reducing the overall severity of the illness. In a comparative analysis of the Phase 3 SIMPLE-severe trial and a retrospective cohort study of severe COVID-19 patients, Remdesivir has recently shown a 62% reduction in the risk of mortality as opposed to the standard of care and an improvement in clinical recovery <a href="#b0210">[42]</a>. The drug is also being tested on outpatients as an inhaled, nebulised form in a Phase 1a trial <a href="#b0215">[43]</a>.</div></p> </div> <div class="lopinavir/ritonavir(lpv/r)" title="sec"><span class="label" tagx="label" title="label">10.1.1.2</span><div class="title" tagx="title" title="title">
Lopinavir/Ritonavir (<i>LPV/r</i>)</div> <p id="p0060">It is an antiviral combination of protease inhibitors that are used to treat HIV infections. Eighty trials are listed on clinical trial registries around the world for testing the drug as a COVID-19 treatment. As Lopinavir has insufficient oral bioavailability (it gets rapidly catabolized by the Cytochrome P450 enzyme system) <a href="#b0220">[44]</a>, ritonavir (a CYP3A4 inhibitor) is added to increase its plasma half-life. Even though LPV/r was found to be effective in retrospective studies on SARS-CoV <a href="#b0225">[45]</a>, it was far less potent than Remdesivir and Chloroquine in-vitro <a href="#b0230">[46]</a>. In a randomized open-label study of 199 patients with COVID-19 (ChiCTR2000029308), LPV/r failed to reduce overall mortality as well as viral load <a href="#b0235">[47]</a>. Thus it is difficult to ascertain whether LPV/r may have an effective role for the treatment of COVID-19 based on the available data. LPV/r has also been discontinued from randomization in the treatment arms of the RECOVERY trial, and the SOLIDARITY trial as it did not demonstrate any beneficial effect in either clinical recovery or mortality <a href="#b0240">[48]</a>, <a href="#b0245">[49]</a>.</p> </div> <div class="oseltamivir" title="sec"><span class="label" tagx="label" title="label">10.1.1.3</span><div class="title" tagx="title" title="title">
Oseltamivir</div> <p id="p0065">Oseltamivir, a neuraminidase inhibitor, is frequently prescribed for the treatment of Influenza. It was prescribed to treat flu-like symptoms in COVID-19 patients at the onset of the outbreak in China before SARS-CoV-2 was identified as the etiologic factor. It has no scientific basis for the treatment of COVID-19 as viruses of the <i>Coronaviridae</i> family do not utilize the enzyme neuraminidase. Moreover, Oseltamivir does not exhibit in-vitro activity against SARS-CoV <a href="#b0250">[50]</a>. Eighteen studies are currently listed for testing the drug on COVID-19 patients. Oseltamivir was shown to be ineffective in the treatment of COVID-19 by an in silico assessment, which also included an in vitro and retrospective study <a href="#b0255">[51]</a>.</p> </div> <div class="favipiravir" title="sec"><span class="label" tagx="label" title="label">10.1.1.4</span><div class="title" tagx="title" title="title">
Favipiravir</div> <p id="p0070">Favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor. It is used in China for the treatment of Influenza and is capable of blocking the replication of other RNA viruses <a href="#b0260">[52]</a> such as arenavirus, filovirus, bunyavirus etc. Favipiravir is activated into its phosphoribosylated form (favipiravir-RTP) in cells, which then inhibits viral RNA polymerase activity <a href="#b0265">[53]</a>. It has shown potential in-vitro activity against SARS-CoV-2 <a href="#b0170">[34]</a>. There are currently 32 studies underway which are aimed at investigating the efficacy of this drug in COVID-19. Favipiravir has been approved for experimental use in COVID-19 patients in Italy, China and Russia <a href="#b0270">[54]</a>, <a href="#b0275">[55]</a>. In a recent multicenter trial in Japan, Favipiravir did not show a significant benefit in mild and moderate COVID-19 cases <a href="#b0280">[56]</a>.</p> </div> <div class="ribavirin" title="sec"><span class="label" tagx="label" title="label">10.1.1.5</span><div class="title" tagx="title" title="title">
Ribavirin</div> <p id="p0075">Ribavirin, a guanosine analog prescribed for viral hemorrhagic fever and respiratory syncytial virus, inhibits viral RNA polymerase and mRNA capping. It has no in-vitro activity against SARS <a href="#b0250">[50]</a>, and is far less potent against SARS-CoV-2 in-vitro than antivirals like Remdesivir <a href="#b0170">[34]</a>. It is associated with hemolytic anemia which could lead to exacerbation of cardiac disease in co-morbid patients. Further, it is also known to be teratogenic.</p> </div> </div> <div class="proteaseinhibitors" title="sec"><span class="label" tagx="label" title="label">10.1.2</span><div class="title" tagx="title" title="title">
Protease inhibitors</div> <div class="camostatmesylate" title="sec"><span class="label" tagx="label" title="label">10.1.2.1</span><div class="title" tagx="title" title="title">
Camostat mesylate</div> <p id="p0080">It is a protease inhibitor that is used for the treatment of chronic pancreatitis. Camostat inhibits the host cell serine protease TMPRSS2 <a href="#b0285">[57]</a>, which primes the viral S protein for entry into human cells. In mice, camostat mesylate showed a 60% survival rate following SARS-CoV infection, at dose concentrations similar to that in humans <a href="#b0290">[58]</a>. It also was found to block viral maturation and entry of SARS-Cov-2 in vitro. Eight trials on COVID-19 are currently underway around the globe.</p> </div> </div> <div class="antimalarial" title="sec"><span class="label" tagx="label" title="label">10.1.3</span><div class="title" tagx="title" title="title">
Antimalarial</div> <div class="hydroxychloroquine/chloroquine(hcq/cq)" title="sec"><span class="label" tagx="label" title="label">10.1.3.1</span><div class="title" tagx="title" title="title">
Hydroxychloroquine / Chloroquine (HCQ/CQ)</div> <p id="p0085">These are antimalarial drugs which are also believed to have antiviral activity <a href="#b0260">[52]</a>. Both HCQ/CQ demonstrated potent in vitro activity against SARS-CoV-2 with an EC<sub>50</sub> of 6.14Â Î¼M and 23.90Â Î¼M, respectively <a href="#b0295">[59]</a>. The drugs have recently gained notoriety due to much sociopolitical hype that has led to a spate of newly launched clinical trials- more than 240 studies are currently underway around the world. There is very limited data to advocate the use of HCQ/CQ as therapeutic options in COVID-19. In a small open-label non-RCT of 36 patients (20 treated/ 16 controls), significantly improved virologic clearance was observed in the HCQ (NÂ =Â 14) group. All six patients in the HCQ plus Azithromycin group had significantly better viral clearance <a href="#b0300">[60]</a>. However, six patients in the HCQ group were removed from the study due to adverse effects or intolerance of the medication. A study in Brazil (NCT04323527) was forced to prematurely halt patient recruitment due to the high fatality rate in the CQ group <a href="#b0305">[61]</a>. The authors of the study opined that treatment providers should refrain from administering high doses of CQ to critically ill patients with COVID-19 because of its potential safety hazards. There was also no reported evidence of a decrease in viral load or improvement in other clinical outcomes. A recent multinational observational study on more than 96,000 patients across six continents reported an increased occurrence of ventricular arrhythmias in patients who received hydroxychloroquine or chloroquine, when used alone or in conjunction with macrolides <a href="#b0310">[62]</a>. The authors reported that the drug regimen did not have any beneficial effect on treatment outcomes in COVID-19 patients, and exhibited an increased risk of mortality in the treatment group as compared to the control. HCQ/CQ has several potential Adverse Drug Reactions (ADR), such as the risk of cardiac arrhythmias (e.g., QT prolongation), GI Disturbances, ECG abnormalities, hypoglycemia, and retinal damage upon long-term/high dose use. In a recent single-center study on 2541 patients, treatment with HCQ alone and HCQÂ +Â Azithromycin demonstrated a significant reduction in mortality among hospitalized COVID-19 patients <a href="#b0315">[63]</a>. However, a randomized double-blind placebo-controlled trial which tested HCQ as postexposure prophylaxis did not find the drug to be effective in preventing COVID-19 after a high-risk exposure <a href="#b0320">[64]</a>. Hydroxychloroquine was discontinued from the RECOVERY trial owing to no evidence of beneficial effect on either mortality or clinical improvement outcomes <a href="#b0325">[65]</a>. The WHO also discontinued the Hydroxychloroquine trial arm of the SOLIDARITY trial as it did not produce any reduction in mortality of COVID-19 patients when compared to the standard of care <a href="#b0245">[49]</a>. Similarly, the FDA has warned against the use of HCQ/CQ as therapeutic interventions against COVID-19 due to the risk of potential ADRs, and has revoked its status as an emergency-use drug for hospitalized patients who are not enrolled in registered clinical trials <a href="#b0330">[66]</a>.</p> </div> </div> </div> <div class="adjunctivepharmacologicaltherapies" title="sec"><span class="label" tagx="label" title="label">10.2</span><div class="title" tagx="title" title="title">
Adjunctive pharmacological therapies</div> <div class="immunomodulatoryagents" title="sec"><span class="label" tagx="label" title="label">10.2.1</span><div class="title" tagx="title" title="title">
Immunomodulatory agents</div> <div class="tocilizumab" title="sec"><span class="label" tagx="label" title="label">10.2.1.1</span><div class="title" tagx="title" title="title">
Tocilizumab</div> <p id="p0090">Tocilizumab is a recombinant monoclonal antibody that inhibits IL-6 receptors and is used for the treatment of rheumatoid arthritis and the â€œcytokine stormâ€� immune overresponse in cancer patients. IL-6 is implicated in immunologic response in patients with Cytokine-release syndromes (CRS). Elevated levels of IL-6 have been associated with hyperinflammatory states and CRS in severe COVID-19 cases and can potentially lead to increased rates of mortality <a href="#b0335">[67]</a>. Patients with thrombocytopenia and neutropenia are at a greater risk of possible ADRs of this drug, which include GI perforation and hepatotoxicity. Sixety two registered trials are currently testing the safety and efficacy of Tocilizumab on COVID-19 patients. A recent study reported that Tocilizumab improved survival, as well as clinical markers in patients with CRS <a href="#b0340">[68]</a>. The drug was also reported to be associated with lower mortality in a cohort of mechanically ventilated COVID-19 patients <a href="#b0345">[69]</a>. However, a retrospective cohort study reported that Tocilizumab did not show a significant difference versus standard care in either clinical improvement or mortality <a href="#b0350">[70]</a>.</p> </div> <div class="sarilumab" title="sec"><span class="label" tagx="label" title="label">10.2.1.2</span><div class="title" tagx="title" title="title">
Sarilumab</div> <p id="p0095">IL-6 Receptor-Inhibiting Monoclonal Antibody that has been previously used in the treatment of Rheumatoid arthritis. It is currently being tested in more than fifteen registered trials targeted at managing the â€œcytokine stormâ€� immune response in severely ill COVID-19 patients. Results from a recent Phase 3 trial showed that Sarilumab did not meet any of the primary or secondary endpoints of the study and is thus ineffective in COVID-19 patients requiring mechanical ventilation <a href="#b0355">[71]</a>.</p> </div> <div class="ruxolitinib" title="sec"><span class="label" tagx="label" title="label">10.2.1.3</span><div class="title" tagx="title" title="title">
Ruxolitinib</div> <p id="p0100">Ruxolitinib has been found to be effective against inflammatory and autoimmune diseases, and is in late-stage development as a topical ointment for atopic dermatitis. Twenty trials are currently testing the efficacy of the drug in COVID-19 patients.</p> </div> <div class="ifx-1" title="sec"><span class="label" tagx="label" title="label">10.2.1.4</span><div class="title" tagx="title" title="title">
Ifx-1</div> <p id="p0105">IFX-1 is a monoclonal antibody designed to induce an anti-inflammatory response by blocking the biological activity of human complement factor C5a. One trial (NCT04333420) is currently being held in the Netherlands to test its efficacy in patients with severe COVID-19, with preliminary results expected by December 31, 2020. It will soon be studied in a Phase 3 trial on patients with severe COVID-19 induced pneumonia after promising results in the earlier phases <a href="#b0360">[72]</a>.</p> </div> </div> </div> <div class="corticosteroids" title="sec"><span class="label" tagx="label" title="label">10.3</span><div class="title" tagx="title" title="title">
Corticosteroids</div> <div class="methylprednisolone" title="sec"><span class="label" tagx="label" title="label">10.3.1</span><div class="title" tagx="title" title="title">
Methylprednisolone</div> <p id="p0110">It is a corticosteroid with potent anti-inflammatory properties which is prescribed for the treatment of arthritis, and has potential benefit in the management of pneumonia. However, data for its use in severe coronavirus diseases is inconclusive and controversial as it shows no impact on clinical outcomes in SARS <a href="#b0365">[73]</a>. Moreover, the benefits are often outweighed by the risks <a href="#b0370">[74]</a> of secondary infection and delayed viral clearance.</p> </div> <div class="dexamethasone" title="sec"><span class="label" tagx="label" title="label">10.3.2</span><div class="title" tagx="title" title="title">
Dexamethasone</div> <p id="p0115">It is a glucocorticoid that has been used for several years in the treatment of various inflammatory and autoimmune diseases. Preliminary results from the RECOVERY trial have shown that Dexamethasone reduces mortality by one-third in mechanically ventilated patients hospitalized with severe COVID-19, and by one-fifth in patients requiring oxygen without mechanical ventilation <a href="#b0375">[75]</a>. The drug did not improve survival in patients not requiring respiratory support. Dexamethasone has been approved for use as a COVID-19 treatment in the UK <a href="#b0380">[76]</a>. As is the case with other corticosteroids, Dexamethasone suppresses the immune system and could thus potentially exacerbate viral infections. However, its immunosuppressant effects might benefit COVID-19 patients who experience CRS.</p> </div> </div> <div class="miscellaneous" title="sec"><span class="label" tagx="label" title="label">10.4</span><div class="title" tagx="title" title="title">
Miscellaneous</div> <div class="nkg2d-ace2car-nkcells" title="sec"><span class="label" tagx="label" title="label">10.4.1</span><div class="title" tagx="title" title="title">
NKG2D-ACE2 CAR-NK cells</div> <p id="p0120">NKG2D is an activating receptor for the immune system's natural killer (NK) cells. SARS-CoV-2 binds to the ACE-2 receptor using its S protein. By targeting the S protein of the virus and NKG2DL on the surface of infected cells with ACE-2 and NKG2D respectively, it is expected that SARS-CoV-2 can be eliminated from the infected cells. Moreover, ACE2 CAR-NK cells can competitively inhibit infection of ATII cells by SARS-CoV-2 through ACE2 receptors, thereby preventing the production of infectious virus particles. A multicenter, randomized Phase 1/2 trial (NCT04324996) is currently testing this cell therapy.</p> </div> <div class="rhace2apn01" title="sec"><span class="label" tagx="label" title="label">10.4.2</span><div class="title" tagx="title" title="title">
RhACE2 APN01</div> <p id="p0125">RhACE- recombinant human angiotensin-converting enzyme 2 is currently undergoing a Phase-2 clinical trial (NCT04335136) in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). This synthetic version of the ACE2 is being studied on 200 participants in Austria to determine if it can prevent viral entry and reduce viral replication in COVID-19 patients. Results from the study are expected in November 2020.</p> </div> <div class="aspirin,clopidogrel,rivaroxaban,atorvastatin,omeprazole" title="sec"><span class="label" tagx="label" title="label">10.4.3</span><div class="title" tagx="title" title="title">
Aspirin, Clopidogrel, Rivaroxaban, Atorvastatin, omeprazole</div> <p id="p0130">These drugs are being trialled to study their cardioprotective effect and prevent direct damage to the heart muscle that appears to exacerbate the severity of COVID-19 in certain patients. The Randomized, open label trial (NCT04333407) will include 3170 patients and will be conducted in the United Kingdom, with a completion date of March 30, 2021.</p> </div> </div> </div> <div class="non-pharmacologicaltherapiesforcovid-19" title="sec"><span class="label" tagx="label" title="label">11</span><div class="title" tagx="title" title="title">
Non-Pharmacological therapies for Covid-19</div> <div class="immunoglobulintherapy" title="sec"><span class="label" tagx="label" title="label">11.1</span><div class="title" tagx="title" title="title">
Immunoglobulin therapy</div> <div class="convalescentplasmatherapy(cp)" title="sec"><span class="label" tagx="label" title="label">11.1.1</span><div class="title" tagx="title" title="title">
Convalescent plasma therapy (CP)</div> <p id="p0135">Inducing passive immunization by infusion of CP is a potential therapeutic option in the absence of a proven anti-viral agent or vaccine. In CP therapy, blood plasma of patients who have recovered from COVID-19 is transfused into patients who are currently ill, in the hope that the freshly-made antibodies will help overcome the virus. Convalescent plasma has previously been used in the treatment of viral diseases such as poliomyelitis, influenza, SARS, and MERS. A case series of five critically ill COVID-19 patients with ARDS reported clinical improvements after the administration of convalescent plasma <a href="#b0385">[77]</a>. Another study on ten severely ill patients in China showed that the clinical symptoms improved significantly within three days, and that the viral load was undetectable after seven days of transfusion <a href="#b0390">[78]</a>. A recent study on more than 20,000 COVID-19 patients who received CP therapy reported that transfusion of CP is safe and does not heighten the risk of adverse events <a href="#b0395">[79]</a>. The study also indicated a reduction in mortality after transfusion of CP. Ianevski et al. reported on the differential nature of immune reactions to COVID-19 in different patients and suggested that the ability of CP to elicit a neutralizing immune response might wane with time <a href="#b0400">[80]</a>. More than 130 listed trials are in progress across the world to gather stronger evidence that would warrant the use of plasma therapy. Plasma banks for the transfusion of CP from freshly recovered COVID-19 patients have been set up in several countries, including India, to counter the rapidly increasing number of cases <a href="#b0405">[81]</a>. Adverse effects associated with plasma transfusion include pathogen transmission and allergic transfusion reactions. The greatest obstacle for a large scale rollout of plasma therapy is to find prospective donors with high levels of neutralizing antibody titer (&amp;gt;1:640) <a href="#b0390">[78]</a>. Studies on SARS have reported that the level of specific neutralizing antibodies titer decreased rapidly within four months of recovery <a href="#b0410">[82]</a>, suggesting that immune protection may wane over time. Such short-lasting humoral immune response suggests that plasma from recently recovered patients is more effective for plasma therapy. The presence of antibodies points to a past infection. However, further research is needed to know more about the type and concentration of virus-neutralizing antibodies that protect against a new infection, and the duration for which the immunity might last. Current data is still insufficient on whether mild or asymptomatic infections generate adequate antibody responses or protection to COVID-19.</p> </div> </div> </div> <div class="vaccines" title="sec"><span class="label" tagx="label" title="label">12</span><div class="title" tagx="title" title="title">
Vaccines</div> <p id="p0140">Vaccination is the best bet for COVID-19 control. DNA plasmids, epitopes, mRNA, and artificial antigen-presenting cells (aAPCs) are some of the biotechnological platforms on which the hunt for a global vaccine is based <a href="#b0415">[83]</a>. Currently, there are no FDA-approved vaccines for COVID-19. There is limited information on the specific antigens used in the development of vaccines against SARS-CoV-2. Most candidate vaccines are aimed at inducing neutralizing antibodies against the viral spike (S) protein, which prevents its uptake via the ACE2 receptor. <a href="#t0010">Table 2</a> provides an overview of the global landscape of COVID-19 vaccine development activity for active clinical trials <a href="#b0420">[84]</a>. The chain of events from conception to market availability of a vaccine usually takes over ten years, and has a mere 6% probability of successful market entry <a href="#b0425">[85]</a>. If a commercially-available SARS-CoV-2 vaccine were to be made available for use in 12â€"18Â months, assuming its path from the lab to the market is unhindered, it would represent a seismic change from the traditional vaccine development pathway. This would require a multipronged strategy involving novel vaccine development paradigms, flexible development phases, ramping up existing manufacturing capacity, unprecedented scale and speed of global R&amp;amp;D, and radical changes in regulatory processes. It will also require careful evaluation of safety and efficacy every step of the way. <div class="table-wrap_UNKNOWN" position="float" id="t0010"><span class="label" tagx="label" title="label">Table 2</span> </div></p><p>COVID-19 vaccine candidates currently enrolled in active clinical trials.</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Name</th> <th>Platform</th> <th>Allocation &amp;amp; Masking</th> <th>Developer</th> <th>Clinical Trial Status</th> <th>Strength</th> <th>Trial Location</th> <th>Estimated Date of Completion</th> <th>References</th> </tr> </thead> <tbody> <tr> <td><b>mRNA 1273</b></td> <td>Lipid nanoparticle encapsulated mRNA vaccine encoding S protein.</td> <td>Randomized; Double blind</td> <td>Moderna/National Institute Of Allergy And Infectious Diseases (NIAID)</td> <td>Phase II trial (NCT04405076)</td> <td>600</td> <td>United States</td> <td>August 2021</td> <td rowspan="8"><a href="#b0415">[83]</a>, <a href="#b0420">[84]</a></td> </tr> <tr> <td><b>Lentiviral Minigene Vaccines (LV-SMENP-DC</b>)</td> <td>Lentiviral vector system (NHP/TYF) used to modify dendritic cells (DCs) and to activate T cells.</td> <td>Non-Randomized; Open Label</td> <td>Shenzhen Geno-Immune Medical Institute</td> <td>Phase I (NCT04276896)</td> <td>100</td> <td>Shenzen, China</td> <td>December 31, 2024</td> </tr> <tr> <td><b>Bacillus Calmette-Guerin (BCG) live-attenuated vaccine*</b></td> <td>Live-attenuated vaccine that induces a broad immune-system response.</td> <td>Randomized; Open Label<br /><br />AND<br /><br />Randomized; Quadruple</td> <td>Murdoch Children's Research Institute;<br /><br />And<br /><br />UMC Utrecht</td> <td>Phase III BRACE trial - (NCT04327206)<br /><br />AND<br /><br />Phase III BCG-CORONA trial - (NCT04328441)</td> <td>4,170 (Australia)<br /><br />AND<br /><br />1500 (Netherlands)</td> <td>Australia<br /><br />AND<br /><br />The Netherlands</td> <td>March 30, 2022<br /><br />AND<br /><br />December 25, 2020</td> </tr> <tr> <td><b>INO-4800</b></td> <td>DNA plasmid vaccine.</td> <td>Non-Randomized; Open Label</td> <td>Inovio Pharmaceuticals<br /><br />AND<br /><br />Coalition For Epidemic Preparedness Innovations (CEPI)</td> <td>Phase I (NCT04336410)</td> <td>40</td> <td>Philadelphia and Kansas City, USA</td> <td>April 2021</td> </tr> <tr> <td><b>AD5-nCov</b></td> <td>Recombinant non-replicating viral vector vaccine. (adenovirus type 5 vector)</td> <td>Non-Randomized; Open Label</td> <td>Cansino Biological Inc./Beijing Institute of Biotechnology</td> <td>Phase I trial (NCT04313127)<br /><br />AND<br /><br />Randomized controlled phase II trial (ChiCTR2000031781)</td> <td>108<br /><br />AND<br /><br />500</td> <td>Wuhan, Hubei, China</td> <td>December 20, 2022 (Phase 1)<br /><br />AND<br /><br />January 2021 (Phase 2)</td> </tr> <tr> <td><b>AZD1222 (PreviouslyChAdOx1 nCoV-19)</b></td> <td>Non-replicating chimpanzee adenovirus vector.</td> <td>Randomized; Single blinded</td> <td>University Of Oxford</td> <td>Phase II/III trial (NCT04400838)</td> <td>10,260</td> <td>United Kingdom</td> <td>August 2021</td> </tr> <tr> <td><b>Pathogen-specific aAPC</b></td> <td>aAPCs modified with lentiviral vector expressing synthetic minigenes.</td> <td>Non-Randomized; Open Label</td> <td>Shenzhen Geno-Immune Medical Institute</td> <td>Phase I (NCT04299724)</td> <td>100</td> <td>Shenzen, China</td> <td>December 31, 2024</td> </tr> <tr> <td><b>CoronaVac (Previously PiCoVacc)</b></td> <td>Formalin-InactivatedÂ +Â alum adjuvant</td> <td>Randomized; Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</td> <td>Sinovac</td> <td>Phase I (NCT04352608)<br /><br />AND<br /><br />Phase II (NCT04383574).</td> <td>143<br /><br />AND<br /><br />600</td> <td>Jiangsu, China</td> <td>December 13, 2020</td> </tr> <tr> <td><b>BNT162</b></td> <td>Four mRNA vaccines: 2 nucleoside modified mRNA-based (modRNA), 1 uridine containing mRNA-based (uRNA), and 1 self-amplifying mRNA-based (saRNA).</td> <td>Non-Randomized; Open Label</td> <td>Pfizer and BioNtech</td> <td>Phase I/II (NCT04380701)</td> <td>200</td> <td>Berlin, Germany</td> <td>August 2020</td> <td /> </tr> <tr> <td><b>Inactivated Vaccine</b></td> <td>Inactivated Novel Coronavirus Pneumonia vaccine (Vero cells)</td> <td>Randomized; Double blind</td> <td>Wuhan Institute of Biological Products<br /><br />AND<br /><br />China National Pharmaceutical Group (Sinopharm)</td> <td>Phase I/II (ChiCTR2000031809)</td> <td>1456</td> <td>Wuhan, China</td> <td>November 2021</td> <td /> </tr> <tr> <td><b>BBIBP-CorV</b></td> <td>Inactivated novel coronavirus (2019-CoV) vaccine (Vero cells)</td> <td>Randomized; Double blind</td> <td>Beijing Institute of Biological Products<br /><br />AND<br /><br />China National Pharmaceutical Group (Sinopharm)</td> <td>Phase II (ChiCTR2000032459)</td> <td>2128</td> <td>China</td> <td>November 2021</td> <td /> </tr> <tr> <td><b>GX-19</b></td> <td>COVID-19 Preventive DNA Vaccine</td> <td>Randomized; Double blind</td> <td>Genexine</td> <td>Phase I/IIa (NCT04445389)</td> <td>190</td> <td>Seoul, Republic of Korea</td> <td>March 2021</td> <td /> </tr> <tr> <td><b>Gam-COVID-Vac</b></td> <td>Non-replicating viral vector COVID-19 vaccine candidate</td> <td>Non-Randomized; Open Label</td> <td>Gamaleya Research Institute,<br /><br />AND<br /><br />Acellena Contract Drug Research and Development</td> <td>Phase I (NCT04436471)</td> <td>38</td> <td>Moscow, Russia</td> <td>August 2020</td> <td /> </tr> <tr> <td><b>mRNA-based vaccine SCB-2019</b></td> <td>Non-chemically modified nucleotides within mRNA for activation of the immune system</td> <td>TBD<sup>**</sup></td> <td>CureVac<br /><br />AND<br /><br />German federal government</td> <td>Phase I (Yet to commence)</td> <td>168</td> <td>Germany and Belgium</td> <td>TBD<sup>**</sup></td> <td /> </tr> <tr> <td><b>SCB-2019</b></td> <td>COVID-19 vaccine candidate that uses Clover's S-Trimer platform, GSK's AS03 adjuvant, and Dynavax's CpG 1018 adjuvant with potassium aluminum sulfate (Alum)</td> <td>Randomized; Triple blind</td> <td>GlaxoSmithKline,Â Sanofi,Â Clover Biopharmaceuticals, DynavaxÂ and Xiamen Innovax</td> <td>Phase I (NCT04405908)</td> <td>150</td> <td>Australia</td> <td>March 2021</td> <td /> </tr> <tr> <td><b>COVAX-19</b></td> <td>Monovalent recombinant protein vaccine</td> <td>Randomized; Triple blind</td> <td>Vaxine Pty Ltd.</td> <td>Phase I (NCT04453852)</td> <td>40</td> <td>Adelaide, Australia</td> <td>July 2021</td> <td /> </tr> <tr> <td><b>bacTRL-Spike</b></td> <td>Bifidobacteria monovalent SARS-CoV-2 DNA oral vaccine candidate</td> <td>Randomized; Triple blind</td> <td>Symvivo</td> <td>Phase I (NCT04334980)</td> <td>112</td> <td>Canada and United States</td> <td>December 2021</td> <td /> </tr> <tr> <td><b>Covaxin (BBV152)</b></td> <td>Inactivated whole-virion vaccine</td> <td>Randomized; Triple blind</td> <td>Bharat Biotech<br /><br />AND<br /><br />National Institute of Virology</td> <td>Phase I/II (NCT04471519)</td> <td>1125</td> <td>India</td> <td>June 2021</td> <td /> </tr> <tr> <td><b>ZyCoV-D</b></td> <td>DNA-plasmid based vaccine</td> <td>TBD<sup>**</sup></td> <td>Zydus Cadila</td> <td>Phase I/II (Yet to commence)</td> <td>1048</td> <td>India</td> <td>2021</td> <td /> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>*- Repurposed Vaccine; Original indication: Tuberculosis (TB) pediatric vaccine **- To-be-declared.</p> </div> <div class="fn-type-" title=""> <p>This table gives an overview of the global COVID-19 vaccine landscape.</p> </div> </div>  <p /> </div> <div class="clinicaltrials" title="sec"><span class="label" tagx="label" title="label">13</span><div class="title" tagx="title" title="title">
Clinical trials</div> <p id="p0145">The sheer volume of clinical trials that are investigating prospective treatment options for COVID-19 emphasizes the need to expedite the production of effective measures to curb its spread and provide much-needed relief to patients and healthcare providers the world over. <a href="#t0015">Table 3</a> summarizes the interventional clinical trials on COVID-19 that have been listed as completed on ClinicalTrials.gov <a href="#b0430">[86]</a>. <div class="table-wrap_UNKNOWN" position="float" id="t0015"><span class="label" tagx="label" title="label">Table 3</span> </div></p><p>Interventional trials on COVID-19 listed as completed on ClinicalTrials.gov.</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>NCT Number</th> <th>Title</th> <th>Interventions</th> <th>Phase</th> <th>Allocation &amp;amp; masking</th> <th>Enrollment no. (age)</th> <th>Primary outcome measures</th> <th>References</th> </tr> </thead> <tbody> <tr> <td>NCT04343768</td> <td>An Investigation Into Beneficial Effects of Interferon Î²-1a, Compared to Interferon Î²-1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial</td> <td>HydroxychloroquineÂ +Â Lopinavir / RitonavirÂ +Â Interferon-Î²-1a<br /><br />VS<br /><br />HCQÂ <b>+</b>Â LPV /rÂ +Â IF-Î²-1b<br /><br />VS<br /><br />Control group: HCQÂ +Â LPV/r</td> <td>Phase 4</td> <td>Randomized; Open Label</td> <td>60 (â‰¥18)</td> <td>Time to clinical improvement</td> <td rowspan="5"><a href="#b0430">[86]</a></td> </tr> <tr> <td>NCT04244591</td> <td>Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial</td> <td>Experimental: standard careÂ +Â Methylprednisolone 40Â mg q12h for 5Â days<br /><br />VS<br /><br />Placebo Comparator: standard care</td> <td>Phase 2 <br /><br />Phase 3</td> <td>Randomized; Open Label</td> <td>80 (â‰¥18)</td> <td>Lower Murray lung injury score</td> </tr> <tr> <td>NCT04291729</td> <td>Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection</td> <td>Experimental: GanovoÂ +Â ritonavir with or without interferon nebulization</td> <td>Phase 4</td> <td>Single Group Assignment;Open Label</td> <td>11 (18 to 75 y/o)</td> <td>Rate of composite adverse outcomes [Â TimeÂ Frame:Â 14Â daysÂ ]</td> </tr> <tr> <td>NCT04261517</td> <td>Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19</td> <td>Experimental: HCQ (400Â mg per day for 5Â days) and conventional treatments<br /><br />VS<br /><br />No Intervention: Conventional treatments</td> <td>Phase 3</td> <td>Randomized; Open Label</td> <td>30(â‰¥18)</td> <td>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3, 5, and 7.<br /><br />The mortality rate of subjects at week 2</td> </tr> <tr> <td>NCT04359251</td> <td>Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study</td> <td>Experimental: Optimizing oxygenation<br /><br />Best oxygenation during PEEP titration<br /><br />VS<br /><br />Experimental: Optimizing compliance<br /><br />Best compliance during PEEP titration<br /><br />VS<br /><br />Experimental: ARDSnet<br /><br />PEEP settings according to ARDSnet table</td> <td>Not Applicable</td> <td>Non-Randomized; Open Label</td> <td>20 (18 to 80 y/o)</td> <td>Respiratory system compliance improvement [Â TimeÂ Frame:Â 20Â minÂ ]</td> </tr> <tr> <td>NCT04358614</td> <td>Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact</td> <td>Cases: Baricitinib Oral Tablet 4 MG /day<br /><br />VS<br /><br />Controls: Standard therapy.</td> <td>Phase 2<br /><br />Phase 3</td> <td>Non-Randomized; Open Label</td> <td>12 (&amp;gt;18 and &amp;lt;75)</td> <td>To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate. [Â TimeÂ Frame:Â 2Â weeksÂ ]</td> <td rowspan="3" /> </tr> <tr> <td>NCT04276688</td> <td>Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</td> <td>Study group: LPV/r 400Â mg/100Â mg twice daily for 14Â daysÂ +Â Ribavirin 400Â mg twice daily for 14Â days + IF Î²-1b 0.25Â mg subcutaneous injection alternate day for 3Â days<br /><br />VS<br /><br />Control group: LPV/r 400Â mg/100Â mg twice daily for 14Â days</td> <td>Phase 2</td> <td>Randomized; Open Label</td> <td>127(â‰¥18)</td> <td>Time to negative nasopharyngeal swab (NPS) 2019-n-CoV coronavirus viral RT-PCR</td> </tr> <tr> <td>NCT04368377</td> <td>Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol</td> <td>Experimental: 25Â Âµg/kg of body weight tirofiban as bolus IV injection (3Â min) followed by continuous infusion at a rate of 0.15Â Âµg /kg/min for 48Â h.<br /><br />Acetylsalicylic acid 250Â mg IV before starting tirofiban, and this will be continued at a dose of 75Â mg daily for 30Â days.<br /><br />A loading dose of clopidogrel 300Â mg PO, followed by 75Â mg daily for 30Â days.<br /><br />Concurrent fondaparinux 2.5Â mgÂ s/c per day for the duration of the hospital stay</td> <td>Phase 2</td> <td>Single Group Assignment;Open Label</td> <td>5(â‰¥18)</td> <td>P/F ratio; <br /><br />PaO2 difference; <br /><br />AND<br /><br />A-a O2 difference at baseline, 24, 48 and 168Â h after treatment initiation</td> </tr> <tr> <td>NCT04324489</td> <td>DAS181 for Severe COVID-19: Compassionate Use</td> <td>Experimental: DAS181 Treatment<br /><br />Patient receives nebulized DAS181 (4.5Â mg BID/day, a total 9Â mg/day) for 10Â days.</td> <td>Not Applicable</td> <td>Single Group Assignment;Open Label</td> <td>4 (18 to 70 y/o)</td> <td>Improved clinical status [Â TimeÂ Frame:Â Day 14Â ] <br /><br />AND<br /><br />Return to room air [Â TimeÂ Frame:Â Day 14Â ]</td> <td /> </tr> <tr> <td>NCT04321421</td> <td>Hyperimmune Plasma for Critical Patients With COVID-19 (COV19-PLASMA)</td> <td>Experimental: administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5</td> <td>Not Applicable</td> <td>Single Group Assignment;Open Label</td> <td>49(â‰¥18)</td> <td>Death [Â TimeÂ Frame:Â within 7Â daysÂ ]</td> <td /> </tr> <tr> <td>NCT04273321</td> <td>Efficacy and Safety of Corticosteroids in COVID-19</td> <td>Experimental: Methylprednisolone 1Â mg/kg/day ivgtt for 7Â days</td> <td>Not Applicable</td> <td>Single Group Assignment;Open Label</td> <td>86(â‰¥18)</td> <td>The incidence of treatment failure in 14Â days [Â TimeÂ Frame:Â 14Â daysÂ ]</td> <td /> </tr> <tr> <td>NCT04378712</td> <td>Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19)</td> <td>Experimental: Intervention Group Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3Â L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.<br /><br />Control Group: Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission</td> <td>Not Applicable</td> <td>Non-Randomized; Open Label</td> <td>90 (18 to 75 y/o)</td> <td>Proportion of patients with improved disease severity at day 2 [Â TimeÂ Frame:Â from baseline to day 2Â ];<br /><br />Proportion of patients with improved disease severity at day 3 [Â TimeÂ Frame:Â from baseline to day 3Â ];<br /><br />AND<br /><br />Proportion of patients with improved disease severity at the day before hospital discharge [Â TimeÂ Frame:Â up to 14Â days (from baseline to the day before hospital discharge)Â ]</td> <td /> </tr> <tr> <td>NCT04280705</td> <td>Adaptive COVID-19 Treatment Trial (ACTT)</td> <td>Experimental: Remdesivir 200Â mg of Remdesivir administered intravenously on Day 1, followed by a 100Â mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10Â days total course. nÂ =Â 286.<br /><br />VS<br /><br />Placebo Comparator: Placebo</td> <td>Phase 3</td> <td>Randomized; Double-blind; Placebo-controlled</td> <td>1062 (18 to 99 y/o)</td> <td>Time to recovery [Â TimeÂ Frame:Â Day 1 through Day 29Â ]</td> <td /> </tr> <tr> <td>NCT04304053</td> <td>Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19)</td> <td>Experimental: Testing, treatment and prophylaxis of SARS-CoV-2<br /><br />Study 1 â€" Contacts receive Hydroxychloroquine prophylaxis. Contacts will complete a survey collecting demographic, epidemiological and clinical and provides a swab for RT-PCR testing at baseline and day 14. Contacts will be offered a prophylactic regimen of hydroxychloroquine (200Â mg tablets) 800Â mg on day 1, and 400Â mg on days 2â€"7.<br /><br />Study 2 â€" Index case receives Hydroxychloroquine. Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3, and 7. Cases will be offered a therapeutic regimen hydroxychloroquine (200Â mg tablets) 800Â mg on day 1, and 400Â mg on days 2â€"7<br /><br />VS<br /><br />Active Comparator: No Intervention- SARS-CoV-2 surveillance<br /><br />Isolation of patient and contact tracing as per national guidelines.</td> <td>Phase 3</td> <td>Randomized; Open Label</td> <td>2300 (â‰¥18)</td> <td>Study 1 â€" Clinical and virological outcome in exposed contacts [Â TimeÂ Frame:Â Up to 14Â days after start of treatmentÂ ]<br /><br />Study 1 â€" Transmission of SARS-CoV-2 in exposed contacts [Â TimeÂ Frame:Â Up to 14Â days after start of treatmentÂ ]<br /><br />Study 2 â€" Virological outcome in index cases [Â TimeÂ Frame:Â Up to 7Â days after start of treatmentÂ ]<br /><br />Study 2 â€" Clinical outcome in index cases [Â TimeÂ Frame:Â Up to 28Â days after start of treatmentÂ ]</td> <td /> </tr> <tr> <td>NCT04331795</td> <td>Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis (COVIDOSE)</td> <td>Experimental: Group A: Tocilizumab (beginning dose 200Â mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24Â h.<br /><br />VS<br /><br />Experimental: Group B: Low-dose tocilizumab (beginning dose 80Â mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24Â h.</td> <td>Phase 2</td> <td>Non-Randomized; Open Label</td> <td>32(â‰¥18)</td> <td>Clinical response [Â TimeÂ Frame:Â Assessed for the 24Â h period after tocilizumab administrationÂ ]<br /><br />Biochemical response [Â TimeÂ Frame:Â Assessed every 24Â h during patient's hospitalization, up to 4Â weeks after tocilizumab administrationÂ ]</td> <td /> </tr> <tr> <td>NCT04473170</td> <td>Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 (SENTAD-COVID)</td> <td>Experimental: Group A<br /><br />Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.<br /><br />The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.<br /><br />VS<br /><br />Active Comparator: Group B<br /><br />COVID-19 Standard care.</td> <td>Phase 1/2</td> <td>Randomized; Open Label</td> <td>146(â‰¥18)</td> <td>Adverse reactions incidence. [Â TimeÂ Frame:Â Day 0â€"28Â ]<br /><br />Rate of mortality within 28-days. [Â TimeÂ Frame:Â Day 0â€"28Â ]<br /><br />Time to clinical improvement on a seven-category ordinal scale. [Â TimeÂ Frame:Â Day 0â€"28Â ]</td> <td /> </tr> <tr> <td>NCT04349241</td> <td>Efficacy and Safety of Favipiravir in Management of COVID-19 (FAV-001)</td> <td>Experimental: Favipiravir in a regimen of 3200Â mg (1600Â mg 12 hourly) loading dose on day-1 followed by 1200Â mg maintenance dose (600Â mg 12 hourly daily) on day-2 to day-10<br /><br />VS<br /><br />Active Comparator: Standard of care therapy<br /><br />Oseltamivir 75Â mg 12 hourly for 5â€"10Â days and Hydroxychloroquine 400Â mg 12 hourly day âˆ’1 followed by 200Â mg 12 hourly daily on day-2 to day-5â€"10.</td> <td>Phase 3</td> <td>Randomized; Open Label</td> <td>100 (18 to 80 y/o)</td> <td>Viral clearance [Â TimeÂ Frame:Â 14Â daysÂ ]<br /><br />Clinical improvement [Â TimeÂ Frame:Â 14Â daysÂ ]</td> <td /> </tr> <tr> <td>NCT04475120</td> <td>Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients</td> <td>Experimental: Group 1a (COVID-19 mild to moderate patients) received liposomal lactoferrin in 200Â mg cps (equal to 100Â mg of lactoferrin), 10 capsules per day for patients weighing less than or equal to 70Â kg divided into 5 capsules in the morning and 5 capsules in the evening for 30Â days for a total of 1Â g of lactoferrin / day; patients with body weight over 70Â kg, 15 capsules per day divided into 3 administrations / day for 30Â days for a total of 1.5Â g of lactoferrin per day; intra-nasal spray: 2 sprays per nostril 3 times a day, inhaling deeply during administration.<br /><br />Group 2a (COVID-19 asymptomatic patients) received liposomal lactoferrin in 200Â mg tablets (equal to 100Â mg of lactoferrin), 5 capsules per day, 3 of which in the morning and 2 in the evening for 30Â days (total dosage 500Â mg of apo-lactoferrin per day); intra-nasal spray: 2 sprays per nostril 3 times a day, inhaling deeply during administration. Before administration, it was recommended to carefully clean the nasal cavity.<br /><br />VS<br /><br />No Intervention: Group 1b<br /><br />15 mild-to-moderate symptomatic patients in hospitalization regimen were enrolled in the control group 1b to be paired by age group and gender to the aforementioned experimental group (1a)<br /><br />Group 2b<br /><br />15 asymptomatic patients were enrolled as a control group (group 2b) to be paired by age group and gender to the aforementioned experimental group (2a)</td> <td>Phase 2/3</td> <td>Randomized; Open Label</td> <td>60(â‰¥20)</td> <td>Rate of viral clearance Time to viral clearance [Â TimeÂ Frame:Â 30Â daysÂ ] time to naso-oro-pharingeal swab negativization</td> <td /> </tr> <tr> <td>NCT04345276</td> <td>Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection</td> <td>Experimental: DanoprevirÂ +Â Ritonavir groupDanoprevir 100Â mg, one tablet each time, twice per day, up to 10Â days. Ritonavir 100Â mg, one tablet each time, twice per day, up to 10Â days.</td> <td>Phase 4</td> <td>Single Group Assignment;Open Label</td> <td>10 (18 to 75 y/o)</td> <td>Rate of composite adverse outcomes [Â TimeÂ Frame:Â Within 10Â days after administrationÂ ]<br /><br />Defined as SPO2Â â‰¤Â 93% without oxygen supplementation, PaO2/FiO2Â â‰¤Â 300Â mmHg or a respiratory rateÂ â‰¥Â 30 breaths per min without supplemental oxygen min without supplemental oxygen</td> <td /> </tr> <tr> <td>NCT04346446</td> <td>Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients</td> <td>Experimental: Convalescent PlasmaÂ +Â Supportive Care Convalescent plasma from recovered COVID-19 patients will be transfused to severely sick COVID-19 infected patients<br /><br />VS<br /><br />Active Comparator: Random Donor PlasmaÂ +Â Supportive Care</td> <td>Phase 2</td> <td>Randomized; Open Label</td> <td>29(â‰¥18)</td> <td>Proportion of patients remaining free of mechanical ventilation in both groups [Â TimeÂ Frame:Â Day 7Â ]</td> <td /> </tr> <tr> <td>NCT04343092</td> <td>Efficacy of Ivermectin as Add on Therapy in COVID19 Patients</td> <td>Experimental: Ivermectin (IVM) 12Â mg /weeklyÂ +Â Hydroxychloroquin (HCQ) 400Â mg/dailyÂ +Â Azithromycin (AZT) 500Â mg daily<br /><br />VS<br /><br />No Intervention: Hydroxychloroquine 400Â mg/dailyÂ +Â azithromycin 500Â mg daily</td> <td>Phase 1</td> <td>Randomized; Double blind</td> <td>100(â‰¥18)</td> <td>Number of cured patients [Â TimeÂ Frame:Â 4Â weeksÂ ]</td> <td /> </tr> <tr> <td>NCT04475588</td> <td>Efficacy and Safety of Itolizumab in COVID-19 Complications</td> <td>Experimental: Best supportive care with Itolizumab<br /><br />Start at 1.6Â mg/kg dose IV infusion, if well tolerated and improvement in patient observed, investigator has the discretion to continue with 1.6Â mg/kg dose every 2Â weeks or 0.8Â mg/kg weekly regimen.<br /><br />VS<br /><br />Active Comparator: Best supportive care</td> <td>Phase 2</td> <td>Randomized; Open Label</td> <td>30(18 to 99 y/o)</td> <td>One-month mortality rate between the two arms [Â TimeÂ Frame:Â One-monthÂ ]</td> <td /> </tr> <tr> <td>NCT04376814</td> <td>Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19</td> <td>Experimental: Test Group<br /><br />In this group, Patients will be given a stat dose of 1600Â mg Favipiravir tablets for the first time, and for next time they will be given 600Â mg of favipiravir tablets three times per day for 7Â days, plus 200Â mg of Hydroxychloroquine two times per day will be given to patients for 7Â days.<br /><br />VS<br /><br />Active Comparator: Control Group<br /><br />In this group, Patients will be given a stat dose of 400Â mg Hydroxychloroquine tablets plus 200/50Â mg of Lopinavir/Ritonavirtwo times per day for seven days.</td> <td>Not Applicable</td> <td>Non-Randomized; Open Label</td> <td>40 (16 to 100y/o)</td> <td>Mortality [Â TimeÂ Frame:Â Up to 28Â daysÂ ]<br /><br />long of hospitalization [Â TimeÂ Frame:Â Up to 28Â daysÂ ]<br /><br />Laboratory Treatment Response (Blood cell count) [Â TimeÂ Frame:Â Up to 28Â daysÂ ]<br /><br />Laboratory Treatment Response (CRP) [Â TimeÂ Frame:Â Up to 28Â daysÂ ]<br /><br />Dyspnea [Â TimeÂ Frame:Â Up to 28Â daysÂ ]<br /><br />Oxygen saturation without supplemental oxygen. [Â TimeÂ Frame:Â Up to 28Â daysÂ ]<br /><br />Oxygen therapy [Â TimeÂ Frame:Â Up to 28Â daysÂ ]</td> <td /> </tr> <tr> <td>NCT04407208</td> <td>Convalescent Plasma Therapy in Patients With COVID-19</td> <td>Experimental: Convalescent plasma recipient<br /><br />Recipients receive 3 times of each 100Â ml convalescent plasma on day 0, 3, and 6</td> <td>Phase 1</td> <td>Single Group Assignment;Open Label</td> <td>10(â‰¥18)</td> <td>Plaque reduction neutralization test (PNRT) [Â TimeÂ Frame:Â day 7 after first transfusionÂ ]<br /><br />D-dimer [Â TimeÂ Frame:Â day 1, 4, 7, 14 after first transfusionÂ ]<br /><br />C-Reactive Protein (CRP) [Â TimeÂ Frame:Â day 1, 4, 7, 14 after first transfusionÂ ]<br /><br />International Normalized Ratio (INR) [Â TimeÂ Frame:Â day 1, 4, 7, 14 after first transfusionÂ ]<br /><br />Oxygenation Index [Â TimeÂ Frame:Â day 1, 4, 7, 14 after first transfusionÂ ]<br /><br />Chest X-ray [Â TimeÂ Frame:Â day 1, 4, 7, 28 after first transfusionÂ ]</td> <td /> </tr> <tr> <td>NCT04342650</td> <td>Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection (CloroCOVID19II)</td> <td>Active Comparator: Intervention<br /><br />CQ 450Â mg twice daily (3 tablets of 150Â mg, every 12Â h) on day 1, followed by CQ 450Â mg once daily (3 tablets of 150Â mg) from D2 to D5. Oral administration.<br /><br />VS<br /><br />Placebo Comparator: Placebo</td> <td>Phase 2</td> <td>Randomized; Quadruple blind</td> <td>152(â‰¥18)</td> <td>Proportion of patients with onset of severe acute respiratory syndrome (SARS) [Â TimeÂ Frame:Â 7Â days after randomizationÂ ]</td> <td /> </tr> <tr> <td>NCT04441424</td> <td>Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients</td> <td>Experimental: Convalescent plasma group<br /><br />400Â ml of convalescent plasma (plasma taken 2Â weeks from the recovered COVID-19 patients) and was transfused over 1â€"2Â h to the recipients by blood donation set.<br /><br />VS<br /><br />Control group<br /><br />The control group of COVID-19 patients were given Hydroxychloroquine 400Â mg PO twice per day for 5Â days and Azithromycin once PO 500Â mg per day for 5Â days.</td> <td>Not Applicable</td> <td>Randomized; Open Label</td> <td>49(â‰¥18)</td> <td>Death versus survival of treated patients [Â TimeÂ Frame:Â Up to 8Â weeksÂ ]</td> <td /> </tr> <tr> <td>NCT04321278</td> <td>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</td> <td>Experimental: HydroxychloroquineÂ +Â azithromycin<br /><br />Hydroxychloroquine [400Â mg 2Ã—/day, 12/12Â h]Â +Â azithromycin [500Â mg 1Ã—/day]<br /><br />VS<br /><br />Active Comparator: Hydroxychloroquine<br /><br />Hydroxychloroquine [400Â mg 2Ã—/day, 12/12Â h]</td> <td>Phase 3</td> <td>Randomized; Open Label</td> <td>440(â‰¥18)</td> <td>Evaluation of the clinical status [Â TimeÂ Frame:Â 15Â days after randomizationÂ ]</td> <td /> </tr> <tr> <td>NCT04323527</td> <td>Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19)</td> <td>Active Comparator: Low Dose Chloroquine Diphosphate (5Â days)<br /><br />Low dose chloroquine group consists of 450Â mg bid (3 tablets of 150Â mgÂ +Â 1 placebo tablet, every 12Â h) on D1, 3 Ã— 150 mg tabletsÂ +Â 1 placebo followed by 4 placebo tablets 12Â h later from D2 to D5, and 4 placebo tablets every 12Â h, D6-D10. Oral administration or via nasogastric tube in case of orotracheal intubation. <br /><br />VS<br /><br />Active Comparator: High Dose Chloroquine Diphosphate (10Â days) consists of 600Â mg bid (4 tablets of 150Â mg, every 12Â h) for 10Â days. Oral administration or via nasogastric tube in case of orotracheal intubation.</td> <td>Phase 2</td> <td>Randomized;<br /><br />Quadruple blind</td> <td>278(â‰¥18)</td> <td>Mortality rate reduction of 50% by day 28 [Â TimeÂ Frame:Â 28Â days after randomizationÂ ]</td> <td /> </tr> <tr> <td>NCT04442958</td> <td>Effectiveness of Convalescent Immune Plasma Therapy</td> <td>Experimental: Convalescent Plasma Therapy Group<br /><br />One dose of 200Â ml of convalescent Ä±mmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.<br /><br />VS<br /><br />No Intervention: Non-Plasma Therapy Group<br /><br />Standart critical care treatment group</td> <td>Not Applicable</td> <td>Randomized; Double blind</td> <td>60(18 to 90 y/o)</td> <td>Plasma ferritin level [Â TimeÂ Frame:Â 7. dayÂ ]<br /><br />Lymphocyte count [Â TimeÂ Frame:Â 7. dayÂ ]<br /><br />D-Dimer level [Â TimeÂ Frame:Â 7. dayÂ ]<br /><br />C-Reactive protein level [Â TimeÂ Frame:Â 7. dayÂ ]<br /><br />Plasma procalcitonin level [Â TimeÂ Frame:Â 7. dayÂ ]<br /><br />Plasma fibrinogen level [Â TimeÂ Frame:Â 7. dayÂ ]</td> <td /> </tr> <tr> <td>NCT04308668</td> <td>Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP)</td> <td>Experimental: Hydroxychloroquine<br /><br />200Â mg tablet; 800Â mg orally once, followed in 6 to 8Â h by 600Â mg, then 600Â mg once a day for 4 consecutive days<br /><br />VS<br /><br />Placebo Comparator: Placebo</td> <td>Phase 3</td> <td>Randomized; Quadruple blind</td> <td>1309(â‰¥18)</td> <td>Incidence of COVID19 Disease among those who are asymptomatic at baseline [Â TimeÂ Frame:Â 14Â daysÂ ] <br /><br />Overall change in disease severity over 14Â days among those who are symptomatic at baseline [Â TimeÂ Frame:Â 14Â daysÂ ]</td> <td /> </tr> <tr> <td>NCT04444986</td> <td>Bioequivalence Study of Favir 200Â mg Film Tablet Kocak Under Fasting Conditions</td> <td>Experimental: Participants first received Favicovir 200Â mg FT in a fasting state. After a washout period of 48Â h, they then received Avigan FT200 mg in a fasting state. <br /><br />VS<br /><br />Experimental: Participants first received Avigan 200Â mg FT in a fasting state. After a washout period of 48Â h, they then received Favicovir FT200 mg in a fasting state.</td> <td>Phase 1</td> <td>Randomized; Open Label</td> <td>30(18 to 40 y/o)</td> <td>AUC0-tlast of favipiravir [Â TimeÂ Frame:Â 0 to 24Â h post-doseÂ ] <br /><br />Cmax of favipiravir [Â TimeÂ Frame:Â 0 to 24Â h post-doseÂ ]</td> <td /> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>This table looks at the interventional trials that have been completed and listed on ClinicalTrials.gov.</p> </div> </div>  <p /> <div class="othernotabletrials" title="sec"><span class="label" tagx="label" title="label">13.1</span><div class="title" tagx="title" title="title">
Other notable trials</div> <p id="p0150">The SOLIDARITY trial is an international collaborative clinical trial initiated by the WHO to help find an effective treatment for COVID-19 in over 100 countries. The trial will assess the efficacy of four treatment options against COVID-19, namely: Remdesivir; LPV/r; LPV/r with Interferon Î²-1a; and HCQ/CQ. Trial arms in multiple countries will help expedite the results to rapidly discover whetherÂ anyÂ of the drugs are effective against SARS-COV-2 <a href="#b0435">[87]</a>. The WHO recently brought the HCQ arm of the SOLIDARITY trial to a halt <a href="#b0440">[88]</a> after reports of a higher mortality rate and an increased risk of adverse effects in patients who received the drug <a href="#b0310">[62]</a> came to light.</p> <p id="p0155">DISCOVERY (NCT04315948) â€" a multi-centre, adaptive, randomized, open label clinical trial to assess the safety and efficacy of treatments of COVID-19 in hospitalized adults, was initiated by the French Institut National de la SantÃ© Et de la Recherche MÃ©dicale (INSERM) as the European counterpart of the SOLIDARITY trial, with the same treatment regimen. The study will be conducted on 3100 patients in seven countries across Europe <a href="#b0445">[89]</a>.</p> <p id="p0160">The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is a multi-centre, randomised controlled trial of over 11,000 patients across the UK. The treatment arms include LPV/r (discontinued due to lack of efficacy), Dexamethasone, HCQ (discontinued), Azithromycin, Tocilizumab, and Convalescent plasma <a href="#b0240">[48]</a>.</p> </div> </div> <div class="futureperspectives" title="sec"><span class="label" tagx="label" title="label">14</span><div class="title" tagx="title" title="title">
Future perspectives</div> <p id="p0165">In order to understand the long-term impact of COVID-19, vigilant follow-up of those recovering from the disease is needed. Previous respiratory diseases brought about by coronaviruses have resulted in deranged lipid and glucose metabolism as well as cardiovascular issues in recovered individuals for up to 12Â years <a href="#b0450">[90]</a>. Widescale serology testing of recovered individuals for the identification of antibodies is key to developing a broader understanding of the disease dynamics of COVID-19. It will also shed light on the neutralizing antibodies, which could potentially act as templates for monoclonal antibody therapies and vaccine candidates in the near future. New diagnostic modalities, serological tests, contact-tracing technologies and disease surveillance tools are essential to reduce the impact of the COVID-19 pandemic, and help prepare for future outbreaks with better preparation and preventive measures.</p> </div> <div class="limitations" title="sec"><span class="label" tagx="label" title="label">15</span><div class="title" tagx="title" title="title">
Limitations</div> <p id="p0170">It is important to acknowledge the limitations of the current study. First, the review only included studies conducted on individuals aged 18 or above. Thus, findings from the studies might not always be generalizable to the pediatric population. Second, the search was limited to only English-language articles which might have been a bottleneck because much of the early data on COVID-19 came from studies which were based in China.</p> </div> <div class="conclusions" title="sec"><span class="label" tagx="label" title="label">16</span><div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0175">In summary, SARS-CoV-2 is a highly contagious novel coronavirus that has rapidly brought about a global pandemic, destroying lives and livelihood at an alarming pace. Even though much is known about its genetic sequence and virology due to our knowledge of its predecessors, several questions regarding the epidemiological properties, transmission and pathogenesis remain unanswered. Animal studies and clinical trials on therapeutics directed against immunopathologic host responses are needed to elucidate the full spectrum of damage caused by this pathogen. Repurposing of existing drugs and the use of non-pharmacological therapies such as Convalescent Plasma are currently the best treatment avenues until a safe and efficacious vaccine is discovered. Although certain prospective agents listed in this review are promising, definitive evidence regarding their effectiveness remains inconclusive. COVID-19 has emerged to be a formidable adversary to the very existence of life as we know it. Overcoming these tough times requires the concerted efforts of people from all walks of life. It necessitates extensive international collaboration between academia, healthcare professionals, pharmaceutical companies, regulators, policymakers, public health organizations and philanthropic associations. The onus on coordinated technical and financial resource mobilization has never been higher, and is indispensable if we are to get the better of this pandemic.</p> </div> <div class="funding" title="sec"> <div class="title" tagx="title" title="title">
Funding</div> <p id="p0180">None.</p> </div> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Declaration of Competing Interest</div> <p id="p0185">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p> </div> </div> <div class="back" title="back"> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="b0005" /><span class="label" tagx="label" title="label">1</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Horby</span><span class="given-names" tagx="given-names" title="given-names">P.W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hayden</span><span class="given-names" tagx="given-names" title="given-names">F.G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gao</span><span class="given-names" tagx="given-names" title="given-names">G.F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A novel coronavirus outbreak of global health concern</span><span class="source" tagx="source" title="source">Lancet</span><span class="volume" tagx="volume" title="volume">395</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">470</span><span class="lpage" tagx="lpage" title="lpage">473</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31986257">31986257</a></span></span></li> <li tag="ref"><a name="b0010" /><span class="label" tagx="label" title="label">2</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huang</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span><span class="source" tagx="source" title="source">Lancet</span><span class="volume" tagx="volume" title="volume">395</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">497</span><span class="lpage" tagx="lpage" title="lpage">506</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31986264">31986264</a></span></span></li> <li tag="ref"><a name="b0015" /><span class="label" tagx="label" title="label">3</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">Q.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</span><span class="source" tagx="source" title="source">N. Engl. J. Med.</span><span class="volume" tagx="volume" title="volume">382</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1199</span><span class="lpage" tagx="lpage" title="lpage">1207</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31995857">31995857</a></span></span></li> <li tag="ref"><a name="b0020" /><span class="label" tagx="label" title="label">4</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhu</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A novel coronavirus from patients with pneumonia in China, 2019</span><span class="source" tagx="source" title="source">N. Engl. J. Med.</span><span class="volume" tagx="volume" title="volume">382</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">727</span><span class="lpage" tagx="lpage" title="lpage">733</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31978945">31978945</a></span></span></li> <li tag="ref"><a name="b0025" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">A.E. Gorbalenya, et al., Severe acute respiratory syndrome-related coronavirus: The species and its viruses â€" a statement of the Coronavirus Study Group, Microbiology (2020). doi:10.1101/2020.02.07.937862.</span></li> <li tag="ref"><a name="b0030" /><span class="label" tagx="label" title="label">6</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guarner</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Three emerging coronaviruses in two decades</span><span class="source" tagx="source" title="source">Am. J. Clin. Pathol.</span><span class="volume" tagx="volume" title="volume">153</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">420</span><span class="lpage" tagx="lpage" title="lpage">421</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32053148">32053148</a></span></span></li> <li tag="ref"><a name="b0035" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">WHO Director-Generalâ€™s opening remarks at the media briefing on COVID-19-11 March 2020 <a href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</a>. (2020). Accessed 28 April 2020.</span></li> <li tag="ref"><a name="b0040" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">WHO Health Emergency Dashboard COVID-19 <a href="https://covid19.who.int/">https://covid19.who.int/</a>. (2020). Accessed 22 July 2020.</span></li> <li tag="ref"><a name="b0045" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 <a href="https://www.who.int/csr/sars/country/table2004_04_21/en/">https://www.who.int/csr/sars/country/table2004_04_21/en/</a>. (2020). Accessed 25 April 2020.</span></li> <li tag="ref"><a name="b0050" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Middle East respiratory syndrome coronavirus (MERS-CoV) <a href="https://www.who.int/emergencies/mers-cov/en/">https://www.who.int/emergencies/mers-cov/en/</a>. (2020). Accessed 25 April 2020.</span></li> <li tag="ref"><a name="b0055" /><span class="label" tagx="label" title="label">11</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van Staden</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">COVID-19 and the crisis of national development</span><span class="source" tagx="source" title="source">Nat. Hum. Behav.</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/s41562-020-0852-7">10.1038/s41562-020-0852-7</a></span></span></li> <li tag="ref"><a name="b0060" /><span class="label" tagx="label" title="label">12</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chan-Yeung</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">R.-H.</span></span></span><span class="mixed-article-title" title="mixed-article-title">SARS: epidemiology</span><span class="source" tagx="source" title="source">Respirology</span><span class="volume" tagx="volume" title="volume">8</span><span class="year" tagx="year" title="year">2003</span><span class="fpage" tagx="fpage" title="fpage">S9</span><span class="lpage" tagx="lpage" title="lpage">S14</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15018127">15018127</a></span></span></li> <li tag="ref"><a name="b0065" /><span class="label" tagx="label" title="label">13</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Killerby</span><span class="given-names" tagx="given-names" title="given-names">M.E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Biggs</span><span class="given-names" tagx="given-names" title="given-names">H.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Midgley</span><span class="given-names" tagx="given-names" title="given-names">C.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gerber</span><span class="given-names" tagx="given-names" title="given-names">S.I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Watson</span><span class="given-names" tagx="given-names" title="given-names">J.T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Middle east respiratory syndrome coronavirus transmission</span><span class="source" tagx="source" title="source">Emerg. Infect. Dis.</span><span class="volume" tagx="volume" title="volume">26</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">191</span><span class="lpage" tagx="lpage" title="lpage">198</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31961300">31961300</a></span></span></li> <li tag="ref"><a name="b0070" /><span class="label" tagx="label" title="label">14</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A pneumonia outbreak associated with a new coronavirus of probable bat origin</span><span class="source" tagx="source" title="source">Nature</span><span class="volume" tagx="volume" title="volume">579</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">270</span><span class="lpage" tagx="lpage" title="lpage">273</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32015507">32015507</a></span></span></li> <li tag="ref"><a name="b0075" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">T.T.-Y. Lam, et al., Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China, Microbiology (2020). doi:10.1101/2020.02.13.945485.</span></li> <li tag="ref"><a name="b0080" /><span class="label" tagx="label" title="label">16</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Forster</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Forster</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Renfrew</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Forster</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Phylogenetic network analysis of SARS-CoV-2 genomes</span><span class="source" tagx="source" title="source">Proc. Natl. Acad. Sci. USA</span><span class="volume" tagx="volume" title="volume">117</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">9241</span><span class="lpage" tagx="lpage" title="lpage">9243</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32269081">32269081</a></span></span></li> <li tag="ref"><a name="b0085" /><span class="label" tagx="label" title="label">17</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lopes</span><span class="given-names" tagx="given-names" title="given-names">L.R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Mattos Cardillo</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Paiva</span><span class="given-names" tagx="given-names" title="given-names">P.B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Molecular evolution and phylogenetic analysis of SARS-CoV-2 and hosts ACE2 protein suggest Malayan pangolin as intermediary host</span><span class="source" tagx="source" title="source">Braz. J. Microbiol.</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s42770-020-00321-1">10.1007/s42770-020-00321-1</a></span></span></li> <li tag="ref"><a name="b0090" /><span class="label" tagx="label" title="label">18</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jaimes</span><span class="given-names" tagx="given-names" title="given-names">J.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">AndrÃ©</span><span class="given-names" tagx="given-names" title="given-names">N.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chappie</span><span class="given-names" tagx="given-names" title="given-names">J.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Millet</span><span class="given-names" tagx="given-names" title="given-names">J.K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Whittaker</span><span class="given-names" tagx="given-names" title="given-names">G.R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop</span><span class="source" tagx="source" title="source">J. Mol. Biol.</span><span class="volume" tagx="volume" title="volume">432</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">3309</span><span class="lpage" tagx="lpage" title="lpage">3325</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32320687">32320687</a></span></span></li> <li tag="ref"><a name="b0095" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Q&amp;amp;A: Similarities and differences â€" COVID-19 and influenza <a href="https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza">https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza</a>. (2020). Accessed 24 April 2020.</span></li> <li tag="ref"><a name="b0100" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment, 7th ed. <a href="http://kjfy.meetingchina.org/msite/news/show/cn/3337.html">http://kjfy.meetingchina.org/msite/news/show/cn/3337.html</a>. (2020). Accessed 25 April 2020.</span></li> <li tag="ref"><a name="b0105" /><span class="label" tagx="label" title="label">21</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van Doremalen</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1</span><span class="source" tagx="source" title="source">N. Engl. J. Med.</span><span class="volume" tagx="volume" title="volume">382</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1564</span><span class="lpage" tagx="lpage" title="lpage">1567</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32182409">32182409</a></span></span></li> <li tag="ref"><a name="b0110" /><span class="label" tagx="label" title="label">22</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jin</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Virology, epidemiology, pathogenesis, and control of COVID-19</span><span class="source" tagx="source" title="source">Viruses</span><span class="volume" tagx="volume" title="volume">12</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">372</span></span></li> <li tag="ref"><a name="b0115" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">J. Kowalski Wladyslaw, T.J. Walsh, V. Petraitis, COVID-19 Coronavirus ultraviolet susceptibility, 2020. doi:10.13140/RG.2.2.22803.22566.</span></li> <li tag="ref"><a name="b0120" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">G. Kampf, A. Voss, S. Scheithauer, Inactivation of coronaviruses by heat, J. Hospital Infect. S0195670120301249 (2020). doi:10.1016/j.jhin.2020.03.025.</span></li> <li tag="ref"><a name="b0125" /><span class="label" tagx="label" title="label">25</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">Z.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shan</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">2019 Novel coronavirus: where we are and what we know</span><span class="source" tagx="source" title="source">Infection</span><span class="volume" tagx="volume" title="volume">48</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">155</span><span class="lpage" tagx="lpage" title="lpage">163</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32072569">32072569</a></span></span></li> <li tag="ref"><a name="b0130" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">M. Faiq, et al., COVID-19: A review on molecular basis, pathogenic mechanisms, therapeutic aspects and future projections, Life Sci. (2020). doi:10.20944/preprints202004.0091.v1.</span></li> <li tag="ref"><a name="b0135" /><span class="label" tagx="label" title="label">27</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sanche</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">Y.T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Romero-Severson</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hengartner</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ke</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2</span><span class="source" tagx="source" title="source">Emerg. Infect. Dis.</span><span class="volume" tagx="volume" title="volume">2020</span><span class="year" tagx="year" title="year">Jul 2020</span><span class="pub-id"><a href="https://dx.doi.org/10.3201/eid2607.200282">10.3201/eid2607.200282</a></span></span></li> <li tag="ref"><a name="b0140" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Therapeutic Options for COVID-19 Currently Under Investigation <a href="https://covid19treatmentguidelines.nih.gov/therapeutic-options-under-investigation/">https://covid19treatmentguidelines.nih.gov/therapeutic-options-under-investigation/</a>. (2020). Accessed 22 April 2020.</span></li> <li tag="ref"><a name="b0145" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">M. Hoffmann, et al., The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells, Mol. Biol. (2020). doi:10.1101/2020.01.31.929042.</span></li> <li tag="ref"><a name="b0150" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">T.-Y. Xiong, S. Redwood, B. Prendergast, M. Chen, Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. ehaa231 (2020). doi:10.1093/eurheartj/ehaa231.</span></li> <li tag="ref"><a name="b0155" /><span class="label" tagx="label" title="label">31</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China</span><span class="source" tagx="source" title="source">Clin. Res. Cardiol.</span><span class="volume" tagx="volume" title="volume">109</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">531</span><span class="lpage" tagx="lpage" title="lpage">538</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32161990">32161990</a></span></span></li> <li tag="ref"><a name="b0160" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">C. Fan, K. Li, Y. Ding, W.L. Lu, J. Wang, ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection, Urology (2020). doi:10.1101/2020.02.12.20022418.</span></li> <li tag="ref"><a name="b0165" /><span class="label" tagx="label" title="label">33</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moreno</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pearson</span><span class="given-names" tagx="given-names" title="given-names">A.D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">How can attrition rates be reduced in cancer drug discovery?</span><span class="source" tagx="source" title="source">Expert Opin. Drug Discov.</span><span class="volume" tagx="volume" title="volume">8</span><span class="year" tagx="year" title="year">2013</span><span class="fpage" tagx="fpage" title="fpage">363</span><span class="lpage" tagx="lpage" title="lpage">368</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23373702">23373702</a></span></span></li> <li tag="ref"><a name="b0170" /><span class="label" tagx="label" title="label">34</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</span><span class="source" tagx="source" title="source">Cell Res.</span><span class="volume" tagx="volume" title="volume">30</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">269</span><span class="lpage" tagx="lpage" title="lpage">271</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32020029">32020029</a></span></span></li> <li tag="ref"><a name="b0175" /><span class="label" tagx="label" title="label">35</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Tawfiq</span><span class="given-names" tagx="given-names" title="given-names">J.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Homoud</span><span class="given-names" tagx="given-names" title="given-names">A.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Memish</span><span class="given-names" tagx="given-names" title="given-names">Z.A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Remdesivir as a possible therapeutic option for the COVID-19</span><span class="source" tagx="source" title="source">Travel Med. Infect. Dis.</span><span class="volume" tagx="volume" title="volume">101615</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.tmaid.2020.101615">10.1016/j.tmaid.2020.101615</a></span></span></li> <li tag="ref"><a name="b0180" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">M.L. Agostini, et al., Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease, mBio 9 (2018) e00221â€"18. /mbio/9/2/mBio.00221-18.atom.</span></li> <li tag="ref"><a name="b0185" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">J. Grein, et al., Compassionate Use of Remdesivir for Patients with Severe Covid-19, N. Engl. J. Med. NEJMoa2007016 (2020). doi:10.1056/NEJMoa2007016.</span></li> <li tag="ref"><a name="b0190" /><span class="label" tagx="label" title="label">38</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</span><span class="source" tagx="source" title="source">Lancet</span><span class="volume" tagx="volume" title="volume">S0140673620310229</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S0140-6736(20)31022-9">10.1016/S0140-6736(20)31022-9</a></span></span></li> <li tag="ref"><a name="b0195" /><span class="label" tagx="label" title="label">39</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. <a href="https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19">https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19</a>. (2020). Accessed 29 April 2020.</span></li> <li tag="ref"><a name="b0200" /><span class="label" tagx="label" title="label">40</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Hopes rise on coronavirus drug remdesivir, <a href="https://www.nature.com/articles/d41586-020-01295-8">https://www.nature.com/articles/d41586-020-01295-8</a>. (2020). Accessed 29 April 2020.</span></li> <li tag="ref"><a name="b0205" /><span class="label" tagx="label" title="label">41</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">COVID-19 therapeutics tracker, <a href="https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker">https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker</a>. Accessed 14 July 2020.</span></li> <li tag="ref"><a name="b0210" /><span class="label" tagx="label" title="label">42</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Gilead reports reduced mortality risk with remdesivir for Covid-19, <a href="https://www.clinicaltrialsarena.com/news/remdesivir-covid-19-analysis-data/">https://www.clinicaltrialsarena.com/news/remdesivir-covid-19-analysis-data/</a>. Accessed 21 July 2020.</span></li> <li tag="ref"><a name="b0215" /><span class="label" tagx="label" title="label">43</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Gilead begins testing of inhaled version of remdesivir for Covid-19, <a href="https://www.clinicaltrialsarena.com/news/gilead-inhaled-remdesivir-phasei/">https://www.clinicaltrialsarena.com/news/gilead-inhaled-remdesivir-phasei/</a>. Accessed 21 July 2020.</span></li> <li tag="ref"><a name="b0220" /><span class="label" tagx="label" title="label">44</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sham</span><span class="given-names" tagx="given-names" title="given-names">H.L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease</span><span class="source" tagx="source" title="source">Antimicrob. Agents Chemother.</span><span class="volume" tagx="volume" title="volume">42</span><span class="year" tagx="year" title="year">1998</span><span class="fpage" tagx="fpage" title="fpage">3218</span><span class="lpage" tagx="lpage" title="lpage">3224</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9835517">9835517</a></span></span></li> <li tag="ref"><a name="b0225" /><span class="label" tagx="label" title="label">45</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chu</span><span class="given-names" tagx="given-names" title="given-names">C.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</span><span class="source" tagx="source" title="source">Thorax</span><span class="volume" tagx="volume" title="volume">59</span><span class="year" tagx="year" title="year">2004</span><span class="fpage" tagx="fpage" title="fpage">252</span><span class="lpage" tagx="lpage" title="lpage">256</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14985565">14985565</a></span></span></li> <li tag="ref"><a name="b0230" /><span class="label" tagx="label" title="label">46</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Wilde</span><span class="given-names" tagx="given-names" title="given-names">A.H.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture</span><span class="source" tagx="source" title="source">Antimicrob. Agents Chemother.</span><span class="volume" tagx="volume" title="volume">58</span><span class="year" tagx="year" title="year">2014</span><span class="fpage" tagx="fpage" title="fpage">4875</span><span class="lpage" tagx="lpage" title="lpage">4884</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24841269">24841269</a></span></span></li> <li tag="ref"><a name="b0235" /><span class="label" tagx="label" title="label">47</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">B. Cao, et al., A trial of Lopinavirâ€"Ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med. NEJMoa2001282 (2020). doi:10.1056/NEJMoa2001282.</span></li> <li tag="ref"><a name="b0240" /><span class="label" tagx="label" title="label">48</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY, <a href="https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery">https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery</a>. Accessed 19 July 2020.</span></li> <li tag="ref"><a name="b0245" /><span class="label" tagx="label" title="label">49</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19, <a href="https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19">https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19</a>. Accessed 19 July 2020.</span></li> <li tag="ref"><a name="b0250" /><span class="label" tagx="label" title="label">50</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tan</span><span class="given-names" tagx="given-names" title="given-names">E.L.C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs</span><span class="source" tagx="source" title="source">Emerg. Infect. Dis.</span><span class="volume" tagx="volume" title="volume">10</span><span class="year" tagx="year" title="year">2004</span><span class="fpage" tagx="fpage" title="fpage">581</span><span class="lpage" tagx="lpage" title="lpage">586</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15200845">15200845</a></span></span></li> <li tag="ref"><a name="b0255" /><span class="label" tagx="label" title="label">51</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Q. Tan, Y. Jin, Ostavimir is ineffective against COVID-19: in silico assessment, in vitro and retrospective study, Infect. Diseases, except HIV/AIDS (2020). doi:10.1101/2020.05.15.20102392.</span></li> <li tag="ref"><a name="b0260" /><span class="label" tagx="label" title="label">52</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">L. Dong, S. Hu, J. Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), 3 (2020).</span></li> <li tag="ref"><a name="b0265" /><span class="label" tagx="label" title="label">53</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Furuta</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Komeno</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nakamura</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</span><span class="source" tagx="source" title="source">Proc. Japan Acad. Ser. B: Phys. Biol. Sci.</span><span class="volume" tagx="volume" title="volume">93</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">449</span><span class="lpage" tagx="lpage" title="lpage">463</span></span></li> <li tag="ref"><a name="b0270" /><span class="label" tagx="label" title="label">54</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Russian Ministry of Health approves the first COVID-19 drug Avifavir produced by JV of RDIF and ChemRar, <a href="https://rdif.ru/Eng_fullNews/5220/">https://rdif.ru/Eng_fullNews/5220/</a>. Accessed 14 July 2020.</span></li> <li tag="ref"><a name="b0275" /><span class="label" tagx="label" title="label">55</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">China Approves Favipiravir (Avigan) As An Experimental Drug To Treat Coronavirus, <a href="https://www.thailandmedical.news/news/china-approves-favipiravir-avigan--as-an-experimental-drug-to-treat-coronavirus">https://www.thailandmedical.news/news/china-approves-favipiravir-avigan--as-an-experimental-drug-to-treat-coronavirus</a>. Accessed 14 July 2020.</span></li> <li tag="ref"><a name="b0280" /><span class="label" tagx="label" title="label">56</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Results from Trial of Antiviral Favipiravir in Patients with Asymptomatic or Mild COVID-19 conducted at Fujita Health University, <a href="https://www.fujita-hu.ac.jp/en/news/kka9ar0000000gmz.html">https://www.fujita-hu.ac.jp/en/news/kka9ar0000000gmz.html</a>. Accessed 14 July 2020.</span></li> <li tag="ref"><a name="b0285" /><span class="label" tagx="label" title="label">57</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">K. Sonawane, et al., Homology modeling and docking studies of TMPRSS2 with experimentally known inhibitors camostat mesylate, nafamostat and bromhexine hydrochloride to control SARS-Coronavirus-2. (2020). doi:10.26434/chemrxiv.12162360.v1.</span></li> <li tag="ref"><a name="b0290" /><span class="label" tagx="label" title="label">58</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Protease inhibitors targeting coronavirus and filovirus entry</span><span class="source" tagx="source" title="source">Antiviral Res.</span><span class="volume" tagx="volume" title="volume">116</span><span class="year" tagx="year" title="year">2015</span><span class="fpage" tagx="fpage" title="fpage">76</span><span class="lpage" tagx="lpage" title="lpage">84</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25666761">25666761</a></span></span></li> <li tag="ref"><a name="b0295" /><span class="label" tagx="label" title="label">59</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yao</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span></span><span class="mixed-article-title" title="mixed-article-title">In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</span><span class="source" tagx="source" title="source">Clin. Infect. Dis.</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1093/cid/ciaa237">10.1093/cid/ciaa237</a></span></span></li> <li tag="ref"><a name="b0300" /><span class="label" tagx="label" title="label">60</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gautret</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</span><span class="source" tagx="source" title="source">Int. J. Antimicrob. Agents</span><span class="volume" tagx="volume" title="volume">105949</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ijantimicag.2020.105949">10.1016/j.ijantimicag.2020.105949</a></span></span></li> <li tag="ref"><a name="b0305" /><span class="label" tagx="label" title="label">61</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">M.G.S. Borba, et al., Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study), Infect. Diseases (except HIV/AIDS), (2020). doi:10.1101/2020.04.07.20056424.</span></li> <li tag="ref"><a name="b0310" /><span class="label" tagx="label" title="label">62</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mehra</span><span class="given-names" tagx="given-names" title="given-names">M.R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Desai</span><span class="given-names" tagx="given-names" title="given-names">S.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ruschitzka</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Patel</span><span class="given-names" tagx="given-names" title="given-names">A.N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</span><span class="source" tagx="source" title="source">Lancet</span><span class="volume" tagx="volume" title="volume">S0140673620311806</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S0140-6736(20)31180-6">10.1016/S0140-6736(20)31180-6</a></span></span></li> <li tag="ref"><a name="b0315" /><span class="label" tagx="label" title="label">63</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arshad</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19</span><span class="source" tagx="source" title="source">Int. J. Infect. Diseases</span><span class="volume" tagx="volume" title="volume">97</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">396</span><span class="lpage" tagx="lpage" title="lpage">403</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32623082">32623082</a></span></span></li> <li tag="ref"><a name="b0320" /><span class="label" tagx="label" title="label">64</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">D.R. Boulware, et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N. Engl. J. Med. NEJMoa2016638 (2020). doi:10.1056/NEJMoa2016638.</span></li> <li tag="ref"><a name="b0325" /><span class="label" tagx="label" title="label">65</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19, <a href="https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19">https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19</a>. Accessed 18 July 2020.</span></li> <li tag="ref"><a name="b0330" /><span class="label" tagx="label" title="label">66</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems, <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or">https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or</a>. Accessed 18 July 2020.</span></li> <li tag="ref"><a name="b0335" /><span class="label" tagx="label" title="label">67</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</span><span class="source" tagx="source" title="source">Lancet</span><span class="volume" tagx="volume" title="volume">395</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1054</span><span class="lpage" tagx="lpage" title="lpage">1062</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32171076">32171076</a></span></span></li> <li tag="ref"><a name="b0340" /><span class="label" tagx="label" title="label">68</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Price</span><span class="given-names" tagx="given-names" title="given-names">C.C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients</span><span class="source" tagx="source" title="source">Chest</span><span class="volume" tagx="volume" title="volume">S0012369220316706</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.chest.2020.06.006">10.1016/j.chest.2020.06.006</a></span></span></li> <li tag="ref"><a name="b0345" /><span class="label" tagx="label" title="label">69</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">E.C. Somers, et al., Tocilizumab for treatment of mechanically ventilated patients with COVID-19. 27.</span></li> <li tag="ref"><a name="b0350" /><span class="label" tagx="label" title="label">70</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Campochiaro</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study</span><span class="source" tagx="source" title="source">Eur. J. Internal Med.</span><span class="volume" tagx="volume" title="volume">76</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">43</span><span class="lpage" tagx="lpage" title="lpage">49</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32482597">32482597</a></span></span></li> <li tag="ref"><a name="b0355" /><span class="label" tagx="label" title="label">71</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Regeneron and Sanofi Provide Update on KevzaraÂ® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients <a href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3">https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3</a>. Accessed 18 July 2020.</span></li> <li tag="ref"><a name="b0360" /><span class="label" tagx="label" title="label">72</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia, <a href="https://www.globenewswire.com/news-release/2020/07/21/2064803/0/en/InflaRx-Announces-Decision-to-Enter-Phase-III-Development-of-IFX-1-in-Severe-COVID-19-Induced-Pneumonia.html">https://www.globenewswire.com/news-release/2020/07/21/2064803/0/en/InflaRx-Announces-Decision-to-Enter-Phase-III-Development-of-IFX-1-in-Severe-COVID-19-Induced-Pneumonia.html</a>. Accessed 21 July 2020.</span></li> <li tag="ref"><a name="b0365" /><span class="label" tagx="label" title="label">73</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stockman</span><span class="given-names" tagx="given-names" title="given-names">L.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bellamy</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Garner</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">SARS: systematic review of treatment effects</span><span class="source" tagx="source" title="source">PLoS Med.</span><span class="volume" tagx="volume" title="volume">3</span><span class="year" tagx="year" title="year">2006</span><span class="fpage" tagx="fpage" title="fpage">e343</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16968120">16968120</a></span></span></li> <li tag="ref"><a name="b0370" /><span class="label" tagx="label" title="label">74</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shang</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hu</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Du</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">On the use of corticosteroids for 2019-nCoV pneumonia</span><span class="source" tagx="source" title="source">Lancet</span><span class="volume" tagx="volume" title="volume">395</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">683</span><span class="lpage" tagx="lpage" title="lpage">684</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32122468">32122468</a></span></span></li> <li tag="ref"><a name="b0375" /><span class="label" tagx="label" title="label">75</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">P. Horby, et al., Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report, Infect. Diseases (except HIV/AIDS), (2020). doi:10.1101/2020.06.22.20137273.</span></li> <li tag="ref"><a name="b0380" /><span class="label" tagx="label" title="label">76</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">World first coronavirus treatment approved for NHS use by government, <a href="https://www.gov.uk/government/news/world-first-coronavirus-treatment-approved-for-nhs-use-by-government">https://www.gov.uk/government/news/world-first-coronavirus-treatment-approved-for-nhs-use-by-government</a>. Accessed 21 July 2020.</span></li> <li tag="ref"><a name="b0385" /><span class="label" tagx="label" title="label">77</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shen</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma</span><span class="source" tagx="source" title="source">JAMA</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1001/jama.2020.4783">10.1001/jama.2020.4783</a></span></span></li> <li tag="ref"><a name="b0390" /><span class="label" tagx="label" title="label">78</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Duan</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Effectiveness of convalescent plasma therapy in severe COVID-19 patients</span><span class="source" tagx="source" title="source">Proc. Natl. Acad. Sci. USA</span><span class="volume" tagx="volume" title="volume">202004168</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1073/pnas.2004168117">10.1073/pnas.2004168117</a></span></span></li> <li tag="ref"><a name="b0395" /><span class="label" tagx="label" title="label">79</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Joyner</span><span class="given-names" tagx="given-names" title="given-names">M.J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients</span><span class="source" tagx="source" title="source">Mayo Clin. Proc.</span><span class="volume" tagx="volume" title="volume">S0025619620306510</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.mayocp.2020.06.028">10.1016/j.mayocp.2020.06.028</a></span></span></li> <li tag="ref"><a name="b0400" /><span class="label" tagx="label" title="label">80</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ianevski</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Potential antiviral options against SARS-CoV-2 infection</span><span class="source" tagx="source" title="source">Viruses</span><span class="volume" tagx="volume" title="volume">12</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">642</span></span></li> <li tag="ref"><a name="b0405" /><span class="label" tagx="label" title="label">81</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Coronavirus India: Rush for plasma therapy as Covid-19 cases rise, <a href="https://www.bbc.com/news/world-asia-india-53387607">https://www.bbc.com/news/world-asia-india-53387607</a>. Accessed 21 July 2020.</span></li> <li tag="ref"><a name="b0410" /><span class="label" tagx="label" title="label">82</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">W.-C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">P.-H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Richardus</span><span class="given-names" tagx="given-names" title="given-names">J.H.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Disappearance of antibodies to SARS-associated coronavirus after recovery</span><span class="source" tagx="source" title="source">N. Engl. J. Med.</span><span class="volume" tagx="volume" title="volume">357</span><span class="year" tagx="year" title="year">2007</span><span class="fpage" tagx="fpage" title="fpage">1162</span><span class="lpage" tagx="lpage" title="lpage">1163</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17855683">17855683</a></span></span></li> <li tag="ref"><a name="b0415" /><span class="label" tagx="label" title="label">83</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">W.-H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Strych</span><span class="given-names" tagx="given-names" title="given-names">U.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hotez</span><span class="given-names" tagx="given-names" title="given-names">P.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bottazzi</span><span class="given-names" tagx="given-names" title="given-names">M.E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The SARS-CoV-2 vaccine pipeline: an overview</span><span class="source" tagx="source" title="source">Curr. Trop. Med. Rep.</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40475-020-00201-6">10.1007/s40475-020-00201-6</a></span></span></li> <li tag="ref"><a name="b0420" /><span class="label" tagx="label" title="label">84</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">DRAFT landscape of COVID-19 candidate vaccines â€" 20 April 2020, <a href="https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf">https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf</a>. (2020). Accessed 01 May 2020.</span></li> <li tag="ref"><a name="b0425" /><span class="label" tagx="label" title="label">85</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pronker</span><span class="given-names" tagx="given-names" title="given-names">E.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Weenen</span><span class="given-names" tagx="given-names" title="given-names">T.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Commandeur</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Claassen</span><span class="given-names" tagx="given-names" title="given-names">E.H.J.H.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Osterhaus</span><span class="given-names" tagx="given-names" title="given-names">A.D.M.E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Risk in vaccine research and development quantified</span><span class="source" tagx="source" title="source">PLoS ONE</span><span class="volume" tagx="volume" title="volume">8</span><span class="year" tagx="year" title="year">2013</span><span class="fpage" tagx="fpage" title="fpage">e57755</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23526951">23526951</a></span></span></li> <li tag="ref"><a name="b0430" /><span class="label" tagx="label" title="label">86</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov: Federally-funded clinical studies related to COVID-19, <a href="https://clinicaltrials.gov/ct2/results%3fcond%3dCOVID-19">https://clinicaltrials.gov/ct2/results?cond=COVID-19</a>. (2020). Accessed 21 July 2020.</span></li> <li tag="ref"><a name="b0435" /><span class="label" tagx="label" title="label">87</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">â€œSolidarityâ€� clinical trial for COVID-19 treatments, <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments</a>. (2020). Accessed 26 April 2020.</span></li> <li tag="ref"><a name="b0440" /><span class="label" tagx="label" title="label">88</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">WHO Director-Generalâ€™s opening remarks at the media briefing on COVID-19 - 25 May 2020, <a href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---25-may-2020">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---25-may-2020</a>. Accessed 31 May 2020.</span></li> <li tag="ref"><a name="b0445" /><span class="label" tagx="label" title="label">89</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vanden Eynde</span><span class="given-names" tagx="given-names" title="given-names">J.J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">COVID-19: a brief overview of the discovery clinical trial</span><span class="source" tagx="source" title="source">Pharmaceuticals</span><span class="volume" tagx="volume" title="volume">13</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">65</span></span></li> <li tag="ref"><a name="b0450" /><span class="label" tagx="label" title="label">90</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Q. Wu, Jing, et al., Altered lipid metabolism in recovered SARS patients twelve years after infection, Sci. Rep. 7 (2017) 9110.</span></li> </ul> </div> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
Acknowledgement</div> <p>Mr. Rohan Chakraborty is a recipient of Junior Research Fellowship from University Grants Commission, India (UGC JRF Ref No: 190510369725). The Grant no. [SR/FST/LS-I/2017/05(C)] and [SR/PURSE Phase 2/39 (C)] received from the Ministry of Science &amp;amp; Technology, Government of India, to Jamia Hamdard is also thankfully acknowledged.</p> </div> </div>  </body></html>